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ABSTRACT
y-Aminobutyric Acid Inhibits Cytokine-Mediated Synergistic 
Induction of Astrocytic Interleukin-6 
Release: A Mechanistic Study
by
Grant Toshio Aguinaldo
Dr. Bryan L. Spangelo, Examination Committee Chair 
Professor of Chemistry 
University of Nevada, Las Vegas
A paucity of y-aminobutyric acid (GABA) levels is thought to encourage 
cytokine release in Alzheimer’s disease (AD). A mechanistic investigation into 
the GABA-mediated suppression of the synergistic release of interleukin (IL)-6 by 
IL-ip and tumor necrosis factor (TNF)-a is presented. Preliminary results 
indicate that p38 and nuclear factor (NF)-kB are essential for the synergistic 
release of IL-6 by IL-ip and TNF-a. Both IL-ip and TN F-a are able to stimulate 
the phosphorylation of p38, however, no synergistic stimulation was observed. 
IL-ip or TNF-a is able to stimulate the degradation of the NF-kB inhibitor, kB-a, 
with no change in kB-p. Interestingly, TNF-a is able to accelerate kB -a  
degradation in the presence of IL-ip. While GABA is unable to suppress kB -a  
degradation and the phosphorylation of p38 by IL-ip and TNF-a, it is postulated 
that GABA may be able to inhibit IL-6 concentrations by lessening the rate of kB - 
a  degradation.
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CHAPTER 1
INTRODUCTION 
Cellular Foundations of the Central Nervous System 
In order to understand the biochemical basis of Alzheimer’s disease (AD) the 
cellular foundations of the central nervous system (CNS) must be discussed. 
The CNS contains two distinct cell types; neurons and glia. Originally termed 
“nerve glue,” glial cells are vital for the safeguarding of neuronal function. 
Neurons are necessary for information transfer, and are classified by the 
endogenous neurotransmitter products produced by each neuronal cell type. 
Glia are characterized by their function and include two general classes; 
microglia and macroglia. Macroglia consist of oligodendrocytes and astrocytes. 
Oligodendrocytes produce myelin sheaths, which function to insulate the axon, 
except at the nodes of Ravier. Astrocytes tend to surround areas close to blood 
vessels, and function to provide metabolic nutrients to their neuronal 
counterparts. Microglia are macrophages that originate from the mesoderm, and 
are found scattered throughout the brain and blood vessels. In response to 
traumatic injury, infection or inflammation, microglial cells become activated and 
release chemical messengers (i.e., cytokines) to localize and repair CNS 
damage.
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Neurotransmission
The movement of information within the vast network within the CNS is 
accomplished through an ensemble of cells and events including neurons, action 
potentials, chemical and electrical synapses, neurotransmitters and postsynaptic 
receptor proteins. Presynaptic neurons receive unidirectional input signals, 
which cause the release of either excitatory or inhibitory neurotransmitters. 
Released neurotransmitters are able to bind to postsynaptic receptors on a 
receptive neuron, which subsequently modify the membrane potentials for either 
excitatory or inhibitory signal propagation.
As shown in Figure 1, synaptic clefts ranging in size from 50 to 300 A 
separate presynaptic and postsynaptic terminals. The two most important 
structures of the presynaptic terminal are mitochondria and neurotransmitter 
vesicles. When an action potential reaches a presynaptic terminal, 
neurotransmitter vesicles undergo exocytosis to release their contents into the 
synaptic cleft. Once a neurotransmitter has entered the synaptic cleft, it is free to 
bind to a specific postsynaptic receptor protein, propagating information transfer 
between two neurons. It is noteworthy that glia do not contain an excitable 
membrane, and are devoid of the ability to transfer information.
Excitotoxicity
In 1986, Steven M. Roth man proposed the concept of excitotoxicity. Glu, the 
primary excitatory neurotransmitter, is toxic to neurons in ischemic stroke and 
traumatic brain injury models (Rothman and Oleny, 1986). This
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Figure 1: Cytoarchitecture of pre- and post-synaptic neurons.
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notion has been extended to suggest a role for excitotoxic insults in AD 
neuropathology, among many other neurodegenerative disorders (Lipton and 
Rosenberg, 1994). Glutamate binds to an array of postsynaptic receptors; 
however, the NMDA subclass of receptors has been particularly implicated in AD 
(Shimizu et al., 2001; Farber et al., 1998).
Postsynaptic receptors for Glu are divided functionally into two classes; 
metabotropic and ionotropic. Metabotropic Glu receptors (mGluR) are coupled to 
G-proteins, and stimulate adenylate cyclase or the metabolism of 
phosphoinositides. lonotropic Glu receptors (IGluR) are ligand-gated ion 
channels selective for N-methyl-D-aspartate (NMDA), kainic acid (KA), or a- 
amino-3-hydroxyl-5-methylisoxazole-4-propionic acid (AMPA) (Figure 2). The 
NMDA receptor has a dual requirement for receptor activation with Glu being a 
primary ligand, and Gly or D-Ser needed as a co-agonist (Figure 36) (Wolosker 
et al., 1996).
Selective blockade of Glu-mediated NMDA receptor activation may be 
beneficial in the treatment AD (Bleich et al., 2003). Mitigating NMDA receptor 
activation is accomplished though an array of competitive and non-competitive 
receptor antagonists (Sonkusare et al., 2005). Of the many antagonists that 
have been tested, the low-to-moderate affinity uncompetitive antagonist 
memantine has shown great clinical promise in treating AD patients suffering 
from severe dementia (Reisberg et al., 2003) (Figure 2).
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Figure 2: Structural projects of various neurochemicals that act at 
postsynaptic Glu receptors.
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Glutamate as a Neurotransmitter 
Glutamate Is the primary excitatory amino acid (EAA) neurotransmitter within 
the CNS, and is involved in fast excitatory synaptic neurotransmission. 
Synthesis of Glu is accomplished through the transamination of the citric acid 
cycle metabolite a-ketoglutarate. Unlike other neurotransmission systems (e.g., 
acetylcholine), there is no enzymatic degradation pathway to remove Glu from 
the synaptic cleft.
Perisynaptic glia are able to regulate glutamatergic responses by their 
intrinsic synaptic removal activity. Glutamate released into the synaptic cleft is 
taken up by glial cells, where the neurotransmitter is subsequently converted into 
Gin using Gin synthetase. Glutamine is then released from the astrocyte and 
converted to Glu within the neuron, completing a single metabolic interconversion 
(Figure 3).
y-Aminobutyric Acid as a Neurotransmitter 
y-Aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the 
CNS. Involved in fast inhibitory synaptic neurotransmission, GABA is largely 
responsible for mediating membrane hyperpolarization. Synthesis of GABA is 
primarily accomplished by the decarboxylation of Glu via glutamic acid 
decarboxylase (GAD). The metabolism and removal of GABA from the synaptic 
cleft is accomplished though the conversion of GABA to succinic semialdehyde 
using GABA-transaminase (GABAT), and the subsequent conversion to succinic
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
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interconversion
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Figure 3; The glutamate-glutamine cycle.
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acid by succinic semialdehyde dehydrogenase (SSDH). Succinic acid is further 
metabolized via the Krebs cycle.
Receptors for GABA are functionally subdivided into two classes: the 
ionotropic GABAa and the metabotropic G ABA b receptors. The ionotropic 
G ABAa receptor conducts Cl" ions and is a mediator of fast inhibitory postsynaptic 
action potentials. G ABAa receptors are heteropentameric structures that are 
widely distributed within the mammalian CNS. In addition to GABA, selective 
activation of the G ABAa receptor can be accomplished by muscimol or 
isoguvacine. Conversely, bicuculline is a competitive G ABA a receptor antagonist 
(Figure 4).
In contrast to the GABAa receptor, the G A B A b is a G-protein-coupled receptor 
that can be directly associated to ion channels though second messenger 
cascades. The actions of the G ABA b receptor are mediated though slow 
inhibitory postsynaptic action potentials. Secondary effects upon G ABA b 
receptor activation include decreasing Ca^  ̂conductance, opening of channels 
and inhibition of adenylyl cyclase. Selective activation of the G ABAb receptor is 
possible with R-(+)-baclofen. Antagonist molecules include phaclofen and 
CGP36742 (Figure 5).
Pathophysiological Hallmarks of Alzheimer’s Disease
Alzheimer’s disease is currently the most common form of dementia among 
the elderly population, affecting twelve million people worldwide (Herbert et al., 
2003). Progressive and selective degeneration of the neural regions necessary
8
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Figure 4; Structural projections of various neurochemicals that act at GABAa 
receptors.
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Figure 5: Structural projections of various neurochemicals that act at 
GABAb receptors.
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for normal mental function is an invariant characteristic of AD. In 1907 Alois 
Alzheimer described the two major neuropathological lesions of AD: extracellular 
senile plaques and intracellular neurofibrillary tangles. To this day, pathologists 
still use these histological hallmarks to identify AD in post-mortem tissue. Twenty 
years later, it was discovered that the senile plaques first described by Alzheimer 
were aggregates of amyloid protein; furthermore, Kang and co-workers reported 
that the sources of these amyloid protein aggregates originate from amyloid 
precursor protein (APP) (Kang et al., 1987).
Amyloid precursor protein (APP) is encoded by a gene located on the short 
arm of chromosome 21. This membrane protein is highly expressed in nerve 
terminals and is important for synaptic terminal formation during development 
(Loffler and Huber, 1992; Selkoe et al., 1988). The exact function of APP in the 
adult brain is currently unknown; however, the role of APP is slowly starting to 
unfold. Currently, reports indicate that APP is selectively enriched in neurons 
(Lahiri and Ge, 2004), undergoes rapid axoplasmic transport (Koo et al., 1990) 
and is up-regulated in response to head injury (Gentleman et al., 1993). It is 
interesting to note that individuals with trisomy 21 (e.g., Down’s syndrome) 
develop AD at an early onset (Wisniewski et al., 1985), suggesting that an 
overexpression of APP accelerates the decrease of mental stability and 
appearance of disease phenotype.
Amyloid precursor protein is enzymatically cleaved by the secretase family of 
enzymes to form (3-amyloid (A(3) peptide fragments (Buxbaum et al., 1998). It 
has been postulated that the cleavage of the hydrophobic portion of APP is a
11
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two-step process, in which a p-secretase cleaves APP to form an amyloidogenic 
C-terminal fragment, which is subsequently cleaved by a y-secretase to form Ap 
peptides ranging in length from 40-43 amino acids (Buxbaum et al., 1998; Spires 
and Hyman, 2005; Selkoe, 1996; Chen and Tang, 2006). p-amyloid protein 
fragments are secreted as monomers (Iwatsubo et al., 1994), but Klein et al. 
have proposed that secreted oligomers and multimers of A pi-42 have the 
propensity to cause neurotoxicity (2001). Although the exact etiology of AD is 
currently unknown, John Hardy proposed that the causative driving force for AD 
is the formation and deposition of Ap plaques. This lesion-centric hypothesis 
became known as the amyloid cascade hypothesis (Hardy and Higgins, 1992). 
The amyloid cascade hypothesis has provided a foundation in which to study AD 
pathogenesis. The hypothesis has not been fully proven, as Terry et al. have 
found a poor connection between the amyloid burden and the decline in mental 
fitness seen in AD (1999).
In addition to Ap plaques, AD neuropathology includes neurofibrillary tangles 
of the low molecular weight microtubule associated protein tau (Aliva, 2006). 
Essential for the maintenance of the axoplasmic transport system, tau is needed 
to mobilize essential nutrients within the neuron. Tau is normally bound to 
tubulin, thus promoting microtubule assembly. In AD, however, tau is dissociated 
from tubulin and forms paired helical filaments (PHF), which promote the 
formation of neurofibrillay tangles. Furthermore, tau PHF are 
hyperphosphorylated at more than 25 sites proximal to the tubulin binding 
domain. Hyperphosphorylated tau is subsequently more resistant to proteolysis.
12
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and as a result is able to form aggregates that interfere with axoplasmic transport 
which culminate in neuronal attrition.
Dysfunctional neurotransmitter systems are another consequence of the 
catastrophic dementia within AD (Bell et al., 2005). These include glutamatergic, 
GABAergic, somatostatinergic, cholinergic, and aceylcholinergic 
neurotransmission systems. Perturbations to these systems include excess 
synaptic release, decreased presence and/or an increased rate of synaptic 
removal. The deterioration of certain neurotransmitters (n.b., GABA, and 
somatostatin) lead to widespread detrimental consequences. The benefit of 
replacing these endogeneous neurotransmitters in AD is demonstrated by the 
administration of the somatostatin (SRIF) analog octreotide, which enhances the 
memory of AD patients in story recall (Craft et al., 1999). Additionally, GABA 
and other GABAa receptor agonists were reported to alleviate Ap-mediated cell 
death in rat cortical and hippocampal neurons in vitro (Lee et al., 2005; Paula- 
Lima et al., 2005; Louzada et al., 2004).
The Interleukin Family of Cytokines
Cytokines are low-molecular weight secreted proteins that modulate many 
cellular processes. The interleukin (IL) family of cytokines is comprised of 18 
different proteins (interleukins 1-18), tumor necrosis factor (TNF), colony 
stimulating factor (CSF), transforming growth factor (TGF), interferons (INF), and 
many other growth factors.
13
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The IL-1 subfamily of cytokines is comprised of three members: IL-1a, IL-ip  
and their intrinsic negative feedback regulator, IL-1 receptor antagonist (IL-Ira). 
Precursor IL-1p is produced as an inactive 31-kDa polypeptide and is processed 
by the IL-ip converting enzyme (ICE) to its mature, non-glycosylated 17-kDa 
construct. The IL -Ira is present both as a secreted and intracellular isoform. 
Both isoforms prevent IL-1 p/IL-1R| receptor ligation. Interleukin-1 p is a 
pleiotropic, pro-inflammatory cytokine with a sophisticated bidirectional 
communication property enabling immune and CNS integration. It is widely 
accepted that IL-ip is one of the many mediators of the insidious 
neuroinflammatory state present in AD.
Numerous reports indicate that the cytokine IL-6 may serve as both an anti- 
(D’Arcangelo et al., 2000; Peng et al., 2005) or pro-inflammatory (Qiu and Groul, 
2003) mediator in AD. Despite the enigmatic nature of this cytokine, past work 
(Spangelo et al., 2004; Zumwalt et al., 1999), and the work presented here show 
that IL-ip is able to drive a p38-mediated signaling cascade culminating in 
release of IL-6 in C6 glioma cells in vitro. Within the context of the studies 
presented, IL-6 is regarded as a pro-inflammatory cytokine. Soluble IL-6 is a 21- 
26-kDa glycosylated protein important in B-cell differentiation and T-cell 
activation.
Tumor necrosis factor-a is a 17.3 kDa non-glycosylated cytokine that induces 
necrosis or cytotoxicity in select tumor cell lines. Tumor necrosis factor-a is up- 
regulated in AD along with IL-ip and may be able to further exacerbate the 
neuroinflammatory state seen in the disorder.
14
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Interleukin-1 p Signal Transduction
Interleukin-1 p signaling is initiated upon its binding to the IL-ip type I receptor 
(IL -IR 1 ) (Akira and Takeda, 2004). A type II receptor functions as a decoy 
receptor for IL-ip as this receptor is devoid of transducing a signal upon ligation. 
Binding of IL-ip to the type I receptor initiates the formation of complex 1, which 
includes IL -IR 1 and the IL-1 receptor accessory protein (IL-1 RAcP) (Figure 6). 
The heterotrimeric complex induces binding of the myeloid differentiation 
primary-response protein 88 (MyD88) to the membrane-bound receptor complex, 
which then recruits the IL-1 receptor associating kinase (IRAK)-4 thereby 
allowing binding of IRAK-1. The binding of IRAKI to the MyD88-IRAK-4 complex 
activates, via phosphorylation, IRAK-1. Subsequent phosphorylation of this 
Ser/Thr kinase results in the binding of TRAF (TNF receptor-associated factor)-6 
to the IRAK-1-MyD88-IRAK-4 complex. The binding of TRAF-6 to the 
phosphorylated IRAK-1 protein results in the disengagement of the TRAF- 
6/phosphorylated-IRAK-1 species from the membrane bound receptor. Binding 
of the newly freed TRAF-6-IRAK-1 complex to another initially membrane bound 
protein complex of TAK-1 binding protein (TAB)-I, TAB-2 and TGF-p-activated 
kinase (TAK)-I induces the phosphorylation of TAK-1. The phosphorylation of 
TAK-1 results in the degradation of IRAK-1; consequently, the TRAF-6-TAK-1 
protein complex is released from the plasma membrane.
The cytosolic TRAF-6-TAK-1-TAB-1-TAB-2 complex leads to the activation of 
ubiquitin-conjugating enzyme 13 (UBC13) and ubiquitin-conjugating enzyme 
variant 1 (UEV1A), which results in the ubiquitination degradation of TRAF-6 in a
15
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proteasome-independent fashion (Akira, 2003). The degradation of TRAF-6 
allows for the fully active TAK-1 protein to selectively activate various signaling 
modules that culminate in the activation of numerous genes though transcription 
factors such as activator protein (AP) -1 and nuclear factor-xB (NF-kB).
The active TAK-1 protein -  commonly referred to as the mitogen-activated 
protein kinase kinase kinase (MARKKK), is a branch point kinase that is able to 
bifurcate IL-ip signal transduction into the mitogen-activated protein kinase 
(MARK) signaling modules, as well as the activation of NF-kB. Activation of the 
MKK3/MKK6 subclass of mitogen-activated protein kinase kinases (MARKK) by 
TAK-1 subsequently leads to an activation of p38 and activation transcription 
factor (ATF)-2. On the other hand, TAK-1 is also able to phosphorylate 
MKK4/MKK7, which causes the activation of c-jun-N-terminal kinase (JNK) and 
c-Jun. Activation of both of these terminal kinase targets is able to induce AR-1 
controlled genes.
Mitogen-Activated Protein Kinase Signaling Modules
The MARK superfamily is central to many different intracellular signaling 
cascades. To date, three different groups of MARKs have been cloned, including 
extracellular-related protein kinase (ERK), JNK, and p38 reactivating kinase 
(p38). Each of these kinases is activated by a dual phosphorylation by their 
respective upstream MARKK, on a Thr-Xaa-Tyr (TXY) motif. The three amino 
acid activation sequence differs for each kinase: ERK (Thr-Glu-Tyr), JNK (Thr-
16
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Figure 6 : Intracellular Initiation of IL-1 signaling.
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Pro-Tyr) and p38 (Thr-Gly-Tyr). Upon activation, each of these MARKs 
phosphorylates a variety of downstream targets to regulate many physiological 
processes within the cell. The best-known downstream targets for each MARK 
are Elk-1, c-Jun and ATF-2 for ERK, JNK and p38, respectively.
Increased activities of p38 and JNK have been observed in numerous rodent 
models of AD (Savage et al., 2002), as well as in post-mortem brain tissue from 
confirmed AD patients (Rearson et al., 2006). The malicious activity of p38 is 
implicated in the hyperphosphorylation of the microtubule associated protein, tau 
(Flensley et al., 1999; Zhu et al., 2000), and in the release of pro-inflammatory 
cytokines (n.b., IL-1 (3 and IL-6 ), which further orchestrate the inflammatory state 
in AD. Culbert et al. have reported that microglia isolated from MAPKAP kinase 
(MK)-2 (a known downstream target of p38 MARK) deficient mice (MK2'^') have 
an impaired release of pro-inflammatory mediators (compared to MK2 ^̂  ̂ mice) 
when stimulated with A(5 1-42, further substantiating the role of p38 MARK in AD 
(2006). In addition, phorbol-ester stimulated APR secretion is sensitive to the 
methoxyflavone inhibitor of ERK, RD98059 (Dessdouits-Magnen et al., 1998) 
(Figure 7). Therapeutic interventions that selectively impinge on the aberrant 
signaling systems in the inflammatory milieu were developed in the 1980s, and 
were termed cytokine-synthesis anti-inflammatory drug (CSAID). It was later 
found that CSAIDs target aberrant p38 MARK signaling.
18
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OCH,
Figure 7: Structural projection of the methoxyflavone inhibitor of ERK 
PD98059.
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Nuclear Factor-KB
Belonging to the Rel protein family, the mammalian NF-k B transcription 
factors are a ubiquitously expressed group of proteins that currently consist of 
p65 (RelA), RelB/p100, c-Rel, NF-KB 1 (p50), and NF-k B2 (p52). Nuclear factor- 
k B is responsible for the coordinate control of the transcription of a battery of 
genes that participate in various pro- and anti-inflammatory roles including IL-ip, 
IL- 6  and TNF-a. The regulation of these Rel proteins is accomplished though the 
combined efforts of [a] subcellular localization within the cytosol, and [b] their 
association with inhibitory proteins such as inhibitor of k B (Ik B) and p100. 
Currently, the Ik B family consists of the three protein isoforms kB -a , kB-p and 
Ik B-8, which function to mask the nuclear localization signal as well as the DNA 
binding domain of the “canonical” NF-k B p65-p50 heterodimer. The activation of 
Ik B kinase (IKK) leads to the phosphorylation, with consequent degradation, of 
Ik B. Two different mechanisms exist for the activation of IKK. In the first, 
MAPKKKs such as the nuclear factor k B inducing kinase (NIK), nuclear-factor k B 
activating kinase (NAK), TAK-1, mitogen activated protein kinase/ERK kinase 
kinase (MEKK)-I, or MEKK-3 stimulate IKK activity within the cytoplasm. A 
second mechanism postulates that IKK is recruited to the cell membrane where 
the phosphorylation and activation of IKK can take place. Once IKK has been 
activated, two putative NF-k B activation pathways exist to activate gene 
transcription. These pathways are referred to as the canonical and non-canonical 
pathways. These pathways are activated in response to different types of stimuli.
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and also differ in activation kinetics with the quicker canonical pathway more 
prevalent within neuroinflammatory signaling.
Within the canonical pathway, cytokines or cellular stresses are able to 
activate a respective MAPKKK, leading to a phosphorylation with subsequent 
activation of Ik B kinase (IKK)-p which is then able to phosphorylate Ik B at distinct 
Ser residues (32 and 36 for kB-a; 19 and 23 for kB-p; 18 and 22 for kB-s). 
Phosphorylated kB  becomes a substrate for the E3'"^ ubiquitin ligase leading to 
the polyubiquitination with subsequent degradation of kB  by the 26S 
proteosome. In the non-canonical pathway, cognate ligands for numerous 
receptors such as B-cell-activating factor receptor, CD40, or the lymphotoxin p 
receptor, stimulate the activity of NIK leading to the activation of IKKa. Active 
IKKa phosphorylates the p i00 portion of the RelB/plOO complex, leading to the 
ubiquitination with subsequent processing of pi 00 to p52. In both cases, the 
nuclear translocation of the free RelB-p52 or p65-p50 heterodimers allows for 
gene transcription upon binding to the NF-k B consensus sequence 5 -GGG ATT 
TTC CC-3’.
Neuroinflammation
Microglia of the CNS perceive amyloid plaques as foreign inclusions and 
initiate an inflammatory response to attack and remove the insoluble deposits. 
Initiation of the inflammatory response results in gliosis and activated microglia, 
causing release of inflammatory cytokines such as IL-ip and IL- 6  (Griffin, 2006). 
Furthermore, CNS levels of IL-ip  and IL- 6  increase in the early stages of AD and
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correlate closely with the severity of the disorder. The amplified release of these 
neuroinflammatory mediators adds a cytokine component to the previously 
described amyloid cascade hypothesis. The additive result of amplified cytokine 
release with the amyloid cascade hypothesis conceivably initiates a destructive 
and recursive cascade of events further exacerbating plaque formation and 
neurodegeneration.
Pro-inflammatory cytokines encourage the development of Ap and tau lesions 
in AD. Yang et al. reported that hippocampal neurons treated with IL-ip respond 
with a two-fold increase in the AP-1-driven APP promoter reporter gene activity, 
suggesting that IL-ip could contribute to AD by up-regulating APP synthesis 
(1998). Interleukin-1 p mediates tau phosphorylation with a concomitant 
decrease in synaptophysin expression in cortical neuron/microglial co-cultures; 
interestingly, the phosphorylation of tau is sensitive to the p38 inhibitor 
SB203580 (Li et al., 2003). These data suggest that IL-ip stimulates p38- 
mediated phosphorylation of tau. In addition, TNF-a, IL-ip and INF-y stimulate 
the y-secretase-mediated cleavage of APP in vitro, a result that is sensitive to the 
anthrapyrazolone inhibitor of JNK, SP600125 (Liao et al., 2004) (Figure 8 ).
Interleukin-1 p is also implicated in the regulation of acetylcholinesterase, a 
postsynaptic enzyme responsible for terminating acetylcholine synaptic 
transmission though neurotransmitter hydrolysis. Li et al. have reported that IL- 
1 p enhances neuronal acetylcholinesterase activity, mRNA, and protein levels in 
vitro and in vivo (2000). Interestingly, inhibition of acetylcholinesterase activity is 
a long-standing drug target for AD. A link between the formation of Ap and
22
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Figure 8 ; Structural projection of the anthrapyrazolone inhibitor of JNK 
SP600125.
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acetlycholinesterse is further substantiated by the findings that 
acetylchoinesterase is able to regulate the processing of APP (Mori et al., 1995).
Hypothesis Statement 
In light of the detrimental role played by pro-inflammatory cytokines in AD, the 
work presented in this thesis stems from two separate but related hypothesis 
statements. The first states that IL-ip  stimulates glutamatergic 
neurotransmission (as monitored by the release of Glu), and exacerbates 
excitotoxic insults mediated by Glu in rat B35 neuroblastoma cells. The second 
hypothesis states that the inhibitory neurotransmitter GABA will selectively 
antagonize p38 MAPK activity during the IL-ip-stimulated release of IL- 6  from rat 
C6  glioma cells.
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CHAPTER 2
MATERIALS AND METHODS 
Chemicals and Reagents 
Orf/70-phthaldehyde (OPA), boric acid, L-Glu, L-Gly, D-glucose, monobasic 
sodium phosphate, y-amino butyric acid (GABA), sodium chloride, potassium 
chloride, calcium chloride, 4-(2-hydroxyethyl)-monosodium salt (HEPES), sodium 
dodecyl sulphate (SDS), tris-(hydroxylmethyl)-amino-methane (Tris), tris- 
(hydroxylmethyl)-amino-methane hydrochloride, Tween-20, dimethyl sulfoxide 
(DMSG), methylthiazolyldiphenyl-tetrazolium bromide (MTT), 2-mercaptoethanol 
(P-ME), bromophenol blue and ammonium persulfate (APS) were obtained from 
Sigma-Aldrich (St. Louis, MO) and were of the highest grade possible. High- 
molecular weight poly-D-lysine (PDL) hydrobromide was obtained from BD 
Biosciences (Bedford, MA). Acrylamide (30%, 37.5:1% bis), and the pre-stained 
protein ladder were obtained from Bio-Rad (Hercules, CA). Dulbecco's Modified 
Eagle Medium (D-MEM), Roswell Park Memorial Institute (RPMI)-1640, PSN 
antibiotic mix, trypsin- ethylenediaminetetraacetic acid (EDTA), heat-inactivated 
fetal bovine serum (FBS), phosphate-buffered saline (PBS) (pH 7.2), N,N,N',N'- 
tetramethylethylenediamine (TEMED) and trypan blue were obtained from 
Invitrogen (Carlsbad, CA). Fetal Clone-1 was obtained from Hyclone (Logan,
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UT). Sodium hydroxide, isopropanol and methanol were obtained from EMD 
Chemicals (Gibbstown, NJ). Bovine serum albumin (BSA) was obtained from 
Gemini Bioproducts (Woodland, CA). Recombinant rat IL-ip, and TNF-a were 
obtained from PeproTech Inc. (Rocky Hill, NJ). Recombinant murine (rm) IL- 6  
was obtained from RD Systems (Minneapolis, MN). Rabbit anti-rat kB -a, kB-p, 
phosphorylated p38 (T180/Y182), total p38, total JNK, mouse anti-rat 
phosphorylated JNK (T183/Y185), and the biotinylated protein ladder was 
obtained from Cell Signaling (Danvers, MA). Goat anti-rabbit and goat anti­
mouse horseradish peroxidase conjugated secondary antibodies were obtained 
from KPL (Gaithersburg, MD). Staurosporine (STS), anisomycin, SB203580, 
SB202190, Bay 11-7082, 6-amino-4-(4-phenoxyphenylethylamino) quinazoline 
(NAI), SP600125, and PD98059 were obtained from EMD Biosciences (La Jolla, 
CA). The rat B35 Neuroblastoma and C6  Glioma cell lines were from the 
American Tissue Type Culture Collection (Rockville, MD). Rat IL- 6  sandwich 
enzyme-linked immunosorbent assay (ELISA) kits, M-PER®, precasted 12% 
SDS- polyacrylamide gel electrophoresis (PAGE) gels, protease and 
phosphatase inhibitor cocktails, and the microBCA® protein assay kit were all 
obtained from Pierce Biotechnology (Rockford, IL). Enhanced 
Chemiluminescence (ECL)-Plus® detection reagent was obtained from 
Amersham (Piscataway, NJ). Schleicher & Schuell Optitran® brand supported 
0.45pm nitrocellulose membranes were obtained from ISC Bioexpress (Kaysville, 
UT). All small molecule inhibitors were initially dissolved in sterile DMSG,
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aliquoted and stored at -20 °C until use (final concentrations of DMSO never 
exceeded 0 .1 % of the final solution).
C6  Glioma Cell Culture 
Rat C6  glioma cells were maintained in continuous culture in a humidified 
atmosphere containing 95% air and 5% CO2  in complete medium (RPMI- 
1640/phenol red, medium containing 10% heat-inactivated FBS, 25 mM HEPES 
pH 7.4, and PSN antibiotic mix). After 3-4 days in culture, cells were removed 
from the tissue culture flasks with 2 mL of 0.25% trypsin/ 0.05% EDTA in Hanks- 
buffered salt solution. The trypsin was inactivated upon the addition of 8  mL of 
complete medium, the cells were subsequently pelleted, the supernatant 
removed, and the pelleted cells resuspended in complete medium. Cell 
suspension densities were determined via coulter particle counter, and cellular 
viability was routinely assessed via trypan blue exclusion. The cells were then 
placed (passed) back into continuous culture (1 x 10® cells/25 cm^-area flask, BD 
Falcon) or were seeded into tissue culture plasticware at the plating densities 
noted for experiments. In all experiments presented, C 6  glioma cells were used 
between passages 5-50.
B35 Neuroblastoma Cell Culture 
Rat B35 neuroblastoma cells were maintained in continuous culture in a 
humidified atmosphere containing 95% air and 5% CO 2  in complete medium (D- 
MEM/phenol red medium containing 10% heat-inactivated FBS, 25 mM HEPES
27
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Inhibitor Associated Effects
SB203580 Direct inhibitor of p38 activity
SB202190 Direct inhibitor of p38 activity
PD98059 Direct inhibitor of ERK activity
SP600125 Direct inhibitor of JNK activity
Bay 11-7082 Prevents the phosphorylation of kB -a
NAI NF-kB activation inhibitor
STS Protein kinase inhibitor and inducer of cytotoxicity
Anisomycin Stimulates phosphorylation of p38
Table 1: Phamacological Inhibitors used in this study and their associated 
effects.
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Entry Inhibitor (percent control)
1 Control 100.00 ± 1.91
2 10 pM SB203580 102.13 + 3.71
3 10 pM SB202190 95 .1 3 11 .8 0
4 10 pM SP600125 27.89 ± 0.65
5 10 pM PD98059 93.68 ±  5.60
6 0.7 nM STS 101.33 + 0.47
7 7 nM STS 100.62 ±0 .96
8 25 pM Bay 11-7082 1.50 + 0.38
9 11 nM NAI 9 6 .2 4 1 5 .1 3
10 1 mM GABA 101 .4612 .98
11 Control 100.00 13 .57
12 10 pM Bay 11-7082 9 8 .4 9 1 1 .6 9
13 25 pM Bay 11-7082 103 .7016 .84
Viability
Entry Inhibitor (percent viable)
14 Control 96 .0816 .71
15 10 pM SP600125 84.87 1 9.30
Net Mitochondrial Activity
Table 2: Viability of C6  glioma cells following a treatment with various 
pharmacological inhibitors. Entries 1-15 represent the net mitochondrial 
activity (as monitored via the metabolism of MTT) of C6  cells that have been 
treated for 24 hours (entries 1-10) or for 15 minutes (entries 11-13). Entries 
14 and 15 represent the cell viability of C6  glioma cells treated with 
SP600125 for 20 hours as quantified via trypan blue exclusion. In all 
treatments, C6  glioma cells were treated with either a vehicle control (serum- 
free RPMI-1640), or the inhibitor indicated. The data are presented as the 
mean ± s.e.m. of triplicate observations obtained from a single representative 
experiment.
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pH 7.4, and PSN antibiotic mix). After 3-4 days in culture, cells were removed 
from the tissue culture flasks with 2 mL of 0.25% tryspin/ 0.05% EDTA in Hanks- 
buffered salt solution. The trypsin was inactivated upon the addition of 8  mL of 
complete medium, the cells were subsequently pelleted, the supernatant 
removed, and the pelleted cells resuspended in complete medium. Cell 
suspension densities were determined via coulter particle counter, and cellular 
viability was routinely assessed via trypan blue exclusion. The cells were then 
placed (passed) back into continuous culture (2x10® cells/25 cm^-area flask, BD 
Falcon) or were seeded into PDL-coated tissue culture plasticware at the plating 
densities noted for experiments. In all experiments presented, B35 
neuroblastoma cells were used between passages 5-35.
7TD1 Hybridoma Cell Culture 
The 7TD1 hybridoma cells were maintained in continuous culture in a 
humidified atmosphere containing 95% air and 5% CO 2  in complete medium 
(RPMI-1640/phenol red, medium containing 5% fetal clone I, 50 pM p-ME, 5 
pg/mL rmlL- 6  and PSN antibiotic mix). After 3-4 days in culture, cells were 
removed from the tissue culture flasks by trituration, and subsequently pelleted, 
the supernatant removed, and the pelleted cells resuspended in complete 
medium. Cell suspension densities determined via coulter particle counter, and 
cellular viability was routinely assessed via trypan blue exclusion. The cells 
were then placed (passed) back into continuous culture (1 x 10® cells/25 cm^-
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area flask, BD Falcon) or were seeded (4 x 10® cells/well) into tissue culture 
plates for IL- 6  release studies using the 7TD1 bioassay.
7TD1-Bioassay for IL- 6  
Rat C 6  glioma cells were plated (125 x 10® cells/well in a 96-well plate) in 
complete medium and allowed 24 h for attachment to the tissue culture plastic. 
Following the attachment period, the cells were washed with serum-free RPMI- 
1640 (2 X 200 pL) and incubated for the indicated time periods with the vehicle 
(sfRPMI-1640) in the presence or absence of IL-ip and other agents for 20 h. 
Post-stimulation, the conditioned medium was removed and either stored at 4 °C 
or assayed for IL- 6  using the 7TD1-bioassay (Spangelo et al., 2004).
During the 7TD1-bioassay, 20 pL of conditioned medium were added to a 96- 
well plate that contained 180 pL of complete medium in the presence of 4 x 10® 
7TD1 cells and left to incubate in a humidified atmosphere containing 95% air 
and 5% CO 2  for 3-4 days. Post incubation, the MTT cell viability assay was 
preformed to quantify the growth of the 7TD1 cells during the incubation period. 
The range of detection (ROD) for the 7TD1-bioassay was between 0.3125 -  320 
pg/mL.
Glutamate Release Experiments 
Rat B35 neuroblastoma cells were seeded (1.5 x 10® cells/well in a PDL- 
coated 12-well plate) in complete medium, and allowed 24 h for attachment to 
tissue culture plastic. Following the attachment period, cells were washed with
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an amino-acid free modified HEPES-buffered Krebs Ringer solution (2 x 1 mL) 
(KRH) (130 mM NaCI, 5 mM KCI, 1.2 mM NaH2 P0 4 , 1.8 mM CaCb, 10 mM 
glucose, 1% BSA, 10 mM NaHCOa and 25 mM HEPES, pH 7.4), and incubated 
for the indicated time periods with the vehicle (KRH) or in the presence of IL-ip. 
A high K* (HK) containing KRH solution was prepared with 85 mM NaCI, 50 mM 
KCI, 1.2 mM NaH2 P0 4 , 1 8  mM CaCb, 10 mM glucose, 1% BSA, 10 mM 
NaHCOs and 25 mM HEPES pH 7.4.
For n minute collection periods, B35 cells were incubated for n minute(s) in 
KRH. Post incubation, the condition medium was removed, and replaced with 
fresh KRH, and incubated for a second n minute incubation period. After the 
second n minute period, the conditioned medium was collected, and replaced 
with HK in the presence or absence of IL-ip and incubated for another n 
minute(s). At the end of the third n minute stimulation period the conditioned 
medium was removed, and replaced with KRH for a fourth n minute incubation 
period. Post-incubation, the conditioned medium was removed and replaced 
with fresh KRH for a fifth and final n minute incubation period. After the fifth 
incubation period, all 5 samples were filtered (0.22 pm), and stored at -80 °C for 
analysis of Glu using HPLC.
Glutamate concentrations were quantitated reversed-phase high performance 
liquid chromatography (HPLC). Two Waters 501 pumps were equipped with a 
0.46 X 50 mm 018 column (Econosphere®, Alltech). Column effluent [sodium 
phosphate (0.1 M, pH 6.0) and methanol] was monitored using a Gilson 
fluorescence detector using excitation and emission wavelength range filters of
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305 -  395 and 430 -  470 nm, respectively. Data was collected using the SR1 
data collection system with the Peak Simple software package. Chromatograms 
were reproduced (by plotting fluorescence intensity against retention time) using 
Sigma Plot® from the raw data obtained from Peak Simple in the American 
Standard Code for Information Interchange (ASCII) format.
HPLC Analysis of Glutamate 
The column was first equilibrated for 15 min by pumping the initial mobile 
phase (0.1 M NaH2 P0 4  pH 6.0 and 70% methanol) through the column at a flow 
rate of 1.0 mL/min. Following the equilibration period, the mobile phase was 
adjusted to 35% methanol where sample injections then took place. All the 
separations used with this column were carried out at a flow rate of 1.0 mL/min. 
Following each separation, the column was allowed to equilibrate for 5 minutes in 
preparation for the injection of another sample.
After a sample was injected, the eluant composition was maintained at 35% 
methanol for 0.5 min. At 0.5 min, a 3.5 min gradient to 70% methanol was 
followed by a 1.5 min gradient to 35% methanol.
Synthesis of OPA Amino Acid Derivatives 
The derivatization reagent was prepared by dissolving OPA (0.270 g, 2.01 
mmol) in 5 mL of methanol. Sodium borate buffer (0.4 M, pH 9.5) (40 mL) and 
p-ME (50 |aL) were then added, and the solution volume was adjusted to 50 mL 
using sodium borate buffer. Roth reported that there is roughly a 500-fold
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decrease in the fluorescence intensity of OPA-derivatized amino acids lacking 
the mercaptan substituent (1971). To avoid the loss in fluorescence intensity due 
to evaporation of p-ME, the derivatization reagent was prepared fresh each day. 
An aliquot of Glu standard was mixed with 0.5 mL of the derivatization reagent 
and allowed to react for 2 min at room temperature according to Scheme 1. After 
2 min, a 10 ^L aliquot was injected onto the HPLC.
MTT Assay for Mitochondrial Viability 
Rat B35 neuroblastoma or C6  glioma cells were plated (125 x 10® cells/well in 
a PDL-coated 96-well plate) in complete medium, and allowed 24 h for 
attachment to the tissue culture plastic. Following the attachment period, the 
cells were washed ( 2  x 2 0 0  |iL) with serum-free medium, and incubated in the 
absence or presence of stimulation agents for the times and doses indicated. 
Post-exposure, net mitochondrial viability was assessed via MTT metabolism 
(Carmichael et al., 1987). In this protocol, 20 pL of a 5 mg/mL MTT solution in 
phosphate-buffered saline (PBS) was added to each well, and incubated at 37 °C 
for 4 h. Post incubation, 150 pL of solution was removed from each well, and 
replaced with 150 pL of a MTT crystal solubilization solution (40 mM HCI in 
isopropanol). Purple formazan crystals (Scheme 2) were quantified after an 
overnight incubation in darkness using a microelisa spectrophotometer set with 
test and reference wavelengths of 570 and 630 nm, respectively. While other 
factors may contribute to changes in mitochondrial activity (i.e., changes that 
could present a false positive in regard to cytotoxicity), a previous report
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Scheme 1: The formation of fluorogenic OPA-derived 1-(2-hydroxylethyl)thio- 
N-substltuted-isolndoles.
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indicates that mitochondrial activity, as assessed via MTT metabolism, provides 
similar results to that of a clonogenic survival (Carmichael et al., 1987).
Cytokine Quantification via ELISA 
Rat C6  glioma cells were plated (125 x 10^/well in a PDL-coated 96-well 
plate) in complete medium and allowed 24 h for attachment to the tissue culture 
plastic. Following the attachment period, the cells were washed (2 x 200 pL) with 
serum-free RPMI 1640 and incubated in serum-free RPMI-1640 in the absence 
or presence of stimulation agents for the times and doses indicatd. Post­
stimulation, cytokine concentrations were assessed via ELISA (Endogen) 
according to the manufacturer’s specifications. The ROD for the commercially 
available ELISA was 31 -  2000 pg/mL.
Collection of Cellular Protein Lysates 
Rat C6  glioma cells were seeded (2.0 x 10^/dish in a PDL-coated 35 x 10 mm 
dish) in complete medium, and allowed 24 h for attachment to the tissue culture 
plastic. Following the attachment period, the cells were washed ( 2 x 2  mL) with 
serum-free RPMI-1640 and incubated in serum-free RPMI-1640 in the absence 
or presence of stimulation agents for the times and doses indicated. Post­
exposure, cells were washed in ice cold PBS, and scraped in 200 |iL of M-PER®  
(Pierce) containing both phosphatase and protease inhibitors (each from Pierce). 
Protein-containing solutions were kept on ice and vortexed every 10 min for a 
total time of no longer than 30 min. Lysates were clarified through centrifugation
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Scheme 2: The conversion of the M IT  substrate to the respective formazan 
product by active mitochondria.
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at 14,000 X g for 10 min at 4 °C. Protein determinations were done via the 
bicinchoninic acid method (Pierce) using BSA as a standard. Protein lysates 
were diluted by 20% using a 2X SDS-PAGE loading buffer (10 % w/v SDS, 2 % 
v/v glycerol, 0.1 % w/v bromophenol blue, 0.5 M Tris pH 6 .8 , and 5% v/v p-ME), 
and boiled for 5 min. Protein lysates were subsequently separated by SDS- 
PAGE, or stored at -80 °C for future analysis.
SDS-PAGE/Western Analysis 
Clarified protein lysates were separated on a SDS-PAGE gel. Poly­
acrylamide gels were either purchased precasted (Pierce) or formed in a Hoffer 
SE-245 gel caster (Amersham) using a 5% stacking gel (3.375 mL H2 O, 625 pL 
1M Tris pH 6 .8 , 50 pL 10% w/v SDS, 825 pL 30% w/v 37.4:1 bis-acrylamide, 50 
pL 10% w/v APS and 5 pL TEMED) and a 12% resolving gel (3.3 mL H2 O, 2.5 
mL 1.5 M Tris pH 8 .8 , 100 pL 10% w/v SDS, 4 mL 30% w/v 37.5:1 bis- 
acrylamide, 100 pL 10% w/v APS, and 4 pL TEMED). The gels were 
subsequently transferred to a Hoffer SE 250 Minivertical Gel Electrophoresis Unit 
(Amersham) filled with SDS-PAGE Tris-Gly (25 mM Tris, 192 mM Gly, and 0.1%  
w/v SDS, pH ~ 8 .8 , note: pH was not adjusted) or Tris-HEPES (0.1 M HEPES, 
0.1 M Tris, 0.1% w/v SDS) (for precasted gels) running buffer, where equal 
amounts of protein (usually 1 0 - 2 5  pg) were loaded into each lane in the 
stacking gel. Biotinylated and prestained protein ladders were also loaded onto 
the stacking gel to determine molecular weight mobility and transfer efficiency, 
respectively. The proteins were electrophoretically separated at 4 °C, using a
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constant voltage of 70 V (100 V for precasted gels) until the bromophenol blue 
dye front was 1 cm from the bottom of the resolving gel. Both gels produced 
identical results, and were used interchangeably.
Following electrophoresis, the proteins were transferred (Hoefer TE22 Mighty 
Small TransPhor Tank, Amersham) to 0.45 pm nitrocellulose membranes at 4 °C, 
using constant amperage of 375 mA, for 90 min in western transfer buffer (25 
mM Tris, 192 mM Gly, and 20% v/v methanol, pH ~ 8 .8 , note: pH was not 
adjusted).
Following the transfer period, protein-containing membranes were [a] 
washed ( 1 x 5  min) in tris-buffered saline containing tween (TBST) (50 mM Tris 
pH 7.4, 150 mM NaCI, and 0.1% v/v Tween-20) for 5 min at 22 °C, [b] blocked 
with TBST containing 5 % nonfat milk (Nestlé Carnation) for 1 h at 22 °C, [c] 
washed ( 3 x 5  min) in TBST at 22 °C, [d] exposed overnight to primary 
antibodies at the dilutions indicated within the text in TBST containing 0.1% BSA 
at 4°C, [e] washed in TBST ( 3 x 5  min), [f] exposed to a horseradish peroxidase 
(HRP)-conjugated secondary (1:5000), and anti-biotin (1:1000) antibodies in 
TBST containing 0.1% BSA for 1 h at 22 °C and [g] washed in TBST ( 3 x 5  min) 
at 22 °C. Proteins were visualized on the Typhoon multipurpose imager using 
the ECL-plus® detectino reagent according to the manufacturer’s specifications 
(Amersham).
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CHAPTER 3
RESULTS 
HPLC Analysis of Amino Acids 
The separation of fluorogenic OPA-derived 1-(2-hydroxylethyl)thio- N- 
substituted-isoindoles has been previously accomplished via reversed-phase 
HPLC within a variety of matrices (Yang et al., 1999; Tcherkas and Denisenko, 
2001; Lindroth and Mopper, 1979). The sensitivity of this method allowed for the 
analytical determination of amino acids released from the rat B35 neuroblastoma 
cell line. Conditioned KRH medium was obtained as outlined in the Materials 
and Methods section, derivatized, and separated via HPLC using the solvent 
program previously described. A sample chromatogram of the basal release of 
amino acids into KRH medium conditioned for 1 min by rat B35 neuroblastoma 
cells is shown in Figure 9. Glutamate was resolved at 2.1 min with a 
fluorescence intensity of 4.28 arbitrary units.
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Figure 9: Representative chromatogram of the separation of Glu via HPLC. 
Rat B35 cells were plated (1.0 x 10® cells/well in a PDL-coated 12-well plate), 
and incubated in KRH for 1 min. Conditioned medium was collected and 
filtered when an aliquot was injected onto HPLC. The arrow indicates the 
elution of Glu from the column. Run specifics; flow rate 1.0 mL/min, injection 
volume: 10 p.L. The data are presented as observations obtained from a 
single representative experiment.
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standard Curve of the HPLC Analysis of Glutamate 
A standard curve for the HPLC analysis of amino acids was generated by 
injecting 10 |iL of Glu standard. The equation for the best fit line between the 
data points was obtained by performing linear regression on the data set 
generated when the maximum relative intensity of each peak was graphed 
against known concentrations of Glu. A representative standard curve is shown 
in Figure 10A, for the range of 0.01 -  10 )liM  Glu, with a correlation coefficient (r )̂ 
> 0.99. Optimum resolution of Glu was achieved with an average retention time 
(Rt) of 1.976 min, using a flow rate of 1 mL/min. A gradient elution of Glu 
occurred at roughly 50% methanol (Figure 10B).
Prior to each amino acid analysis, a 5 )liM standard of Glu was injected, to 
monitor the drift in the column. A new calibration plot was generated if the known 
standard differed by more than 5% (with respect to both retention time and 
fluorescence intensity) compared to the 5 )aM intensity on the previous standard 
curve.
Stimulated Release of Glutamate from B35 Cells 
Neurotransmission within the CMS is controlled by a plethora of mechanisms 
involving the intricate interaction of different factors and stimuli. In order to 
validate the HPLC quantification of amino acids, rat B35 neuroblastoma cells 
were incubated under depolarizing conditions using a KRH solution adjusted to 
contain 50 mM K  ̂ (Numakawa et al., 2002). When B35 cells were incubated for
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Figure 10: Stan(dard curve for the HPLC analysis of Glu. Increasing 
concentrations of Glu standard (0.01 -  10 jaM) in KRH were made. 
Subsequently, 10 p,L of each standard were injected onto the HPLC. The 
best-fit line (panel A) was obtained via linear regression of the maximum peak 
height versus each respective standard concentration. Panel B is a 
representative elution of a Glu peak (5 pM) superimposed over the solvent 
program for the first 5 min. Run specifics: average Rt = 1.976, flow rate 1 
mL/min, effluent composition B = methanol. Equation of the best fit line: y = 
402.61X + 0.1695; r̂  = 0.9957. The data are presented as observations 
obtained from a single representative experiment.
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1, 3, or 5 minute(s) in 50 mM (HK), there was no apparent release of Glu as 
indicated through HPLC (a representative figure illustrating these observations is 
shown n Figure 11 A. Similarly, 85 mM and 130 mM also failed to depolarize 
B35 cells (data not shown). Numakawa et al. reported that basic fibroblast 
growth factor (BFGF) simulates the release of Glu from cultured rat cortical 
neurons (2002). The pro-inflammatory cytokine IL-ip was tested for its ability to 
stimulate release of the excitatory neurotransmitter Glu from B35 cells. When 
B35 cells were incubated with 25 ng/mL IL-ip, a concentration that is successful 
for IL- 6  release by C 6  cells (Spangelo et al., 2004), for 1, 3, or 5 minute(s) there 
was no apparent release of Glu as monitored via HPLC (Figure 11B). Due to the 
fact that HK and IL-ip could synergistically stimulate Glu release (Numakawa et 
a., 2002) from B35 cells, B35 cells were incubated in the presence of 50 mM K̂  
and 25 ng/mL IL-ip for 1, 3, or 5 minute(s). As shown in Figure 11C, the 
combined presence of these two agents once again failed to stimulate release of 
Glu from this cell line.
Staurosporine-Mediated Apoptosis 
The alkaloid toxin staurosporine (STS: Figure 12B) is known to be a positive 
stimulator of apoptosis (Couldwell et al., 1994) and an effective non-specific 
inhibitor of protein kinase C (PKC) (Friedman LM et al., 1997; Rüegg et al., 1989) 
at micromolar and nanomolar concentrations, respectively. In preliminary trials, 
STS’s ability to compromise cell viability was assessed via the mitochondrial
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Figure 11: Stimulated release of Glu from B35 cells. Rat B35 cells were 
plated (1 X 10® cells/well in a PDL-coated 12-well plate) and treated for 
various time periods [ (^ )  1 min), ( t ) 3 min, (♦) 5 min]. Post treatment, Glu 
content in conditioned medium was determined via HPLC analysis. KRH 
represents a treatment group where B35 neuroblastoma cells were treated 
with the KRH vehicle alone; a (+) indicates that B35 neuroblastoma cells were 
treated with 50 mM K  ̂ (K, panel A), 25 ng/mL IL-ip (IL, panel B) or both 50 
mM K̂  and 25 ng/mL IL-ip (K & IL, panel C). Each hatch mark on the 
abscissa represents a Glu-collection time period in the presence of the noted 
solution. The data are presented as a single representative experiment.
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metabolism of MTT in the B35 neuroblastoma cell line. Compared with the 
vehicle control (KRH), increasing STS concentrations were able to produce dose- 
dependent reductions in net mitochondrial activity (IC 5 0  = 0.441 pM) as 
determined via the metabolism of MTT (Figure 12A). For example, 0.2 pM STS 
caused a modest 2% decrease in cell viability. However, when 1 pM STS was 
used, a 98 % decrease in cell viability was seen in comparison to the control.
Glutamate-Mediated Cytotoxicity
The finding that B35 cells are capable of responding to cytotoxic stimuli 
prompted the investigation of the excitotoxic effects of the primary excitatory 
neurotransmitter, Glu. Reductions in the mitochondrial activity of B35 cells were 
dependent on Glu concentrations and initial cell densities (Figure 13). A 
maximal suppression of net mitochondrial activity (-70% ) was achieved at 10 
mM Glu using a cell density of 15 x 10® cells/well (Figure 13A). A 25% reduction 
in activity was seen using both 20 x 10® and 40 x 10® cells/well, at 10 mM Glu 
(Figure 13). Conversely, the sensitivity of 5 x 10® cells/well was greatest at 5 mM 
Glu (Figure 13B).
The cytotoxic effects of Glu could not be substantiated in a new line of B35 
neuroblastoma cells. As shown in Figure 14B, concentrations that were proven 
to be successful in previous studies (i.e.. Figure 13), were unable to cause a 
reduction in mitochondrial activity, using a low and high passage number (9 and 
20, respectively). In addition, B35 cells were not sensitized by overnight
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Figure 12: Staurosporine-mediated apoptosis In B35 cells. Rat B35 cells (100 
X 10  ̂ cells/well In a PDL-coated 96-well plate) were treated with vehicle 
control (KRH) or Increasing concentrations of STS for 24 hours. Post- 
Incubatlon, net mitochondrial activity was assessed via the metabolism of 
MTT. (B) Structural projection of STS. The data are presented as mean ± 
s.e.m. of quadruplicate observations obtained from a single representative 
experiment.
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incubations in a reduced serum environment (0, 5, or 10 % FBS) followed by a 
24-hour treatment with Glu (Figure 14A). The inability of B35 cells to respond as 
postulated in Hypothesis 1 prompted an investigation into Hypothesis 2.
Standard Curve Comparison Between the 7TD1-Bioassay and the Rat IL-6
ELISA
In all previous reports from the Spangelo laboratory, the 7TD1-bioassay has 
been used in the quantification of IL-6 released from C6 glioma cells and other 
cell types (Zumwalt et al., 1999; Spangelo et al., 2004; Spangelo and Jarvis, 
1996). Although highly sensitive for the determination of IL-6, the 7TD1-bioassay 
has intrinsic limitations that limit the use of this quantification method. The most 
prominent of these are the shape and restricted region (i.e., the “linear” portion till 
~80 pg/mL) of the standard curve generated by the 7TD1-bioassay (Figure 15). 
Other limitations include the fact that stimulation agents must be properly chosen 
such that they will not interfere with the viability of both the C6 glioma and 7TD1 
hybridoma cell lines. To circumvent the intrinsic limitations of the 7TD1- 
bioassay, the work presented here made use of commercially available ELISA 
kits that were specific for rat IL-6 (i.e., mouse IL-6 is not detected). When a 
comparison is made between the standard curves generated by the 7TD1- 
bioassay and ELISA kits, it becomes evident that although the bioassay has 
roughly a 100-fold lower ROD (0.3125 -  320 pg/mL), the ELISA is able to 
quantify more concentrated samples with a ROD of 31 -  2000 pg/mL.
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Figure 13: Glutamate-mediated cytotoxicity in B35 cells. Rat B35 cells were 
plated at differing densities as shown and treated with a vehicle control (KRH) 
or increasing concentrations of Glu for 24 hours. Post-incubation, net 
mitochondrial activity was assessed via the metabolism of MTT. Passage 
numbers: 29 and 30 for panels A and B, respectively. Data presented are the 
mean ± s.e.m. of quadruplicate observations obtained from two separate 
experiments.
49
ReprocJucecJ with perm ission o f the copyright ow ner. Further reproctuction prohibitect w ithout perm ission.
Ï  _  1 0 0  ■
il
I 0%FBS 
] 5% FBS 
I 10% FBS
0 1 5
(mM) 
glutamate
I Passage 9 
I Passage 20
(mM)
glutamate
125
100
•75
• 50
• 25 
0
II
Figure 14: Effects of serum and passage number on Glu-mediated 
cytotoxicity in B35 cells. Rat B35 cells were plated (100 x 10^ cells/well in a 
PDL-coated 96-well plate) in varying serum conditions (A) or complete 
medium (B) and treated with a vehicle control (KRH) or increasing 
concentrations of Glu for 24 hours. Post incubation, net mitochondrial activity 
was assessed via the metabolism of MTT. The data are presented as mean 
± s.e.m. of quadruplicate observations obtained from a single representative 
experiment.
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Figure 15: Comparison between the standard curves from the 7TD1-bioassay 
and the rat IL-6 ELISA. (A ) y = (5.349 x 10‘>  + 0.1040; î  = 0.998; ROD 31 
-  2000 pg/mL ( t ) y = 0.1809 Ln (x) + 0.1375; r̂  = 0.972; ROD 0.3125 -  320 
pg/mL. The data are presented as mean ± s.e.m. of triplicate observations 
obtained from a single representative experiment. The error bars (n = 3 for 
both the 7TD1-bioassay and ELISA) have been omitted to increase figure 
clarity.
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ELISA Quantification of Rat IL-6: Standard Curve and the Effects of Serum 
To determine the effect of a carrier protein in the ELISA as indicated in the 
manufacturer’s protocol (Pierce product number, ER2IL6), a standard curve of 
recombinant rat IL-6 was generated using either serum-free RPMI-1640 (0% 
FBS) or RPMI-1640 supplemented with 5% FBS (5% FBS). Immunoreactive IL-6 
was analyzed via ELISA, where the best fit line between the absorbance and 
respective IL-6 concentrations was generated. As shown in Figure 16, the 
presence of 5% FBS had no effect on the standard curve. All ELISA experiments 
were performed for IL-6 in the absence of FBS.
The IL-ip-Stimulated Release of IL-6: Effects of Serum 
The presence of 5% FBS did not have an effect on the immunoreactivity of 
IL-6 within the ELISA. Interestingly, the presence of 5% FBS did effect the ability 
of IL-ip  to stimulate the release of IL-6 from C6 glioma cells. As shown in Figure 
17, the presence of 5% FBS led to a three-fold reduction (121.98 ± 18.34 pg/mL) 
compared to 0% FBS (343.21 ± 26.64 pg/mL) in the IL-ip-stimulated release of 
IL-6. All standard curves for ELISA quantifications were done in the absence of 
serum
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Figure 16: Effects of serum on the standard curve for the rat IL-6 ELISA. A 
standard curve was generated using either serum-free RPMI-1640, or RPMI- 
1640 containing 5% FBS and quantitated using the Pierce rat IL-6 ELISA 
according to the manufacturer’s specifications. Regression equations, and 
correlation coefficients (a ) y = (5.349 x 10" )̂x + 0.1040; r̂  = 0.999 (t ) y = 
(5.998 X 10"’̂ )x + 0.0755; r  = 0.997. The data are presented as mean ± 
s.e.m. of triplicate observations obtained from a single representative 
experiment.
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Figure 17; Effects of serum on the IL-ip-stimulated release of IL-6. Rat C6 
cells (125 X 10^ cells/well In a 96-well plate) were treated with a vehicle 
control (RPMI-1640 containing either 0% or 5% FBS) or 50 ng/mL IL-ip for 20 
hours. Post stimulation, conditioned medium was removed and assayed for 
IL-6 using Pierce ELISA according to the manufacturer’s specifications. A (*) 
indicates that the concentration of IL-6 could not be detected by ELISA. Data 
presented are the mean ± s.e.m. of quadruplicate observations of a single 
experiment.
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Synergistic Release of IL-6 by IL-ip and TNF-a  
Zumwalt et al. reported that TNF-a and IL-ip (Tl) are able to synergistically 
stimulate the release of IL-6 from rat C6 glioma cells (1999). The quantification 
of IL-6 from this prior study was done using the 7TD1-bioassay, which is prone to 
artifact. Due to the nature of the 7TD1-bioassay, the synergistic effect of Tl was 
revisited using ELISA quantification of rat IL-6. As shown in Figure 18, 50 ng/mL 
IL-ip and 100 ng/mL TNF-a produced a striking 20-fold increase in the release of 
IL-6 (2327.82 ± 159.95 pg/mL) compared to 50 ng/mL IL-ip alone (119.53 ± 8.05 
pg/mL). Interestingly, 100 ng/mL TNF-a had only a marginal effect on the 
release of IL-6 (58.07 ± 4.21 pg/mL) when compared to control (32.95 ± 18.05 
pg/mL). These data are in accord with the previous observations of Zumwalt et 
al. (1999).
Synergistic Release of IL-6 by IL-ip and TNF-a: MARK Contribution 
Spangelo et al. have previously reported that p38 is essential for the IL-ip- 
stimulated release of IL-6 (2004). To ascertain the roles of p38, JNK and ERK in 
the synergistic release of IL-6 by Tl, 0 6  glioma cells were pretreated with 10 jilVI 
SB203580, SB202190, PD98059, or SP600125 followed by a co-treatment with 
each inhibitor and 50 ng/mL IL-ip and 100 ng/mL TNF-a. As shown in Figure 
19A, inhibition of p38 activity using SB203580 or its hydroxyl-phenyl analogue 
SB202190 (Figure 190) completely blocked the release of IL-6 by Tl. For 
example, when SB203580 was used, an IL-6 concentration of 64.07 ± 5.88 
pg/mL was observed in comparison to Tl alone
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Figure 18: Synergistic release of IL-6 by IL-ip and TNF-a. Rat C6 cells were 
plated (125 x 10^ cells/well in a PDL-coated 96-well plate) in complete 
medium and treated with a vehicle control (serum-free RPMI-1640), 50 ng/mL 
IL-ip, 100 ng/mL TNF-a, or both TNF-a, and IL -ip  for 20 hours. Post­
stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. The data are 
presented as mean ± s.e.m. of quadruplicate observations obtained from a 
single representative experiment.
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(973.78 + 54.58 pg/mL). Furthermore, SB202190 (100.22 ± 8.00 pg/mL) caused 
an impressive 94% suppression of IL-6 when compared to Tl (1541.22 ± 242.48 
pg/mL). Inhibition of JNK activity using SP600125 (Figure 19D), was unable to 
provide a similar substantial suppression of IL-6 release (759.95 ± 68.36 pg/mL 
versus Tl alone, 1541.22 ± 242.48 pg/mL). Lastly, inhibition of ERK activity using 
PD98059, (Figure 19B) also was unable to suppress the release of IL-6 by Tl 
(709.89 ± 42.28 pg/mL versus Tl alone, 973.78 ± 54.58 pg/mL). These data 
substantiate the role of p38 in the synergistic release of IL-6 by Tl.
GABA Inhibition of the Synergistic Release of IL-6 by IL-ip and TNF-a 
The GABA-mediated suppression of the IL-ip-driven release of IL-6 has been 
reported (Spangelo et al., 2004). To determine if GABA has the propensity to 
inhibit the synergistic release of IL-6 by Tl, C6 cells were pretreated for 1 h with 1 
mM GABA followed by a 20 h co-treatment of 1 mM GABA, 50 ng/mL IL-ip and 
100 ng/mL TNF-a. As shown in Figure 20, GABA was able to produce a 2.5-fold 
suppression of the synergistic release of IL-6 release by 100 ng/mL TNF-a and 
50 ng/mL IL-ip in C6 cells. In the presence of Tl, an IL-6 concentration of
973.78 ± 54.58 pg/mL was measured. When C6 cells were pretreated for 1-hour 
with 1 mM GABA, and co-treated with GABA, TNF-a and IL-ip, for 20 hours IL-6 
concentrations were suppressed by 67% (382.85 ± 30.90 pg/mL).
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Figure 19: MARK contribution to the synergistic release of IL-6 by IL-1(3 and 
TNF-a. Rat C6 cells were plated (125 x 10^ cells/well in a PDL-coated 96- 
well plate) and were pretreated with 10 îM SB203580 (A), PD98059 (B), 
SB202190 (C), SP60G125 (D), or for 1 hour and co-treated with 10 
SB203580, SB202190, SP600125, or PD98059, 50 ng/mL IL-ip and 100 
ng/mL TNF-a for 20 hours. Post stimulation, conditioned medium was 
removed and assayed for IL-6 using Pierce ELISA according to the 
manufacture’s specifications. (E) Structural projections of SB203580 and 
SB202190. A (+) indicates that C6 glioma cells were treated with IL-ip, TNF- 
a, and the inhibitor; a (-) indicates that cells were treated with the inhibitor 
alone. The data are presented as mean ± s.e.m. of quadruplicate 
observations obtained from a single representative experiment.
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Figure 20: GABA inhibition of the synergistic release of IL-6 by IL-ip and 
TNF-a. Rat C6 cells were plated (125 x 10^ cells/well in a PDL-coated 96- 
well plate) and were pretreated with 1 mM GABA for 1 hour and co-treated 
with 1 mM GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post 
stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. A (+) indicates 
that C6 glioma cells were treated with IL-ip, TNF-a, and the inhibitor; a (-) 
indicates that cells were treated with the inhibitor alone. The data are 
presented as mean ± s.e.m. of quadruplicate observations obtained from a 
single representative experiment.
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Synergistic Release of IL-6 by IL-ip and TNF-a: Role of PKA 
To determine the role of protein kinase A (PKA) in the synergistic release of 
IL-6 release, rat C6 glioma cells were pretreated with 7 nM STS for 1 hour, and 
co-treated with 7 nM STS, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. 
Post stimulation, conditioned medium was collected and assayed for IL-6 content 
via the rat IL-6 ELISA. As shown in Figure 21, 7 nM STS modestly reduced the 
synergistic release of IL-6 by Tl. These data suggest that cellular signaling 
through PKA is not imperative for the synergistic release of IL-6 by Tl.
Synergistic Release of IL-6 by IL-ip and TNF-a: Role of PKC 
The data presented by Zumwalt et al., suggest that PKC could be an 
indispensable kinase in the synergistic release of IL-6 by Tl (1999). To verify the 
role of PKC in the synergistic release of IL-6 by Tl, C6 cells were pretreated with 
0.7 nM STS -  a concentration that selectively inhibits PKC isoforms (Rüegg et 
al., 1989). As shown in Figure 22, STS caused a 3.5-fold suppression of the 
synergistic release of IL-6 by Tl (i.e., the synergistic release was reduced from
973.78 ± 54.58 pg/mL to 281.14 + 25.05 pg/mL of IL-6).
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Figure 21: PKA contribution to the synergistic release of IL-6 by IL-ip and 
TNF-a. Rat C6 cells were plated (125 x 10^ cells/well in a PDL-coated 96- 
well plate) and were pretreated with 7 nM STS for 1 hour and co-treated with 
7 nM STS, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post 
stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. A (+) indicates 
that C6 glioma cells were treated with IL-ip, TNF-a, and the inhibitor; a (-) 
indicates that cells were treated with the inhibitor alone. The data are 
presented as mean ± s.e.m. of quadruplicate observations obtained from a 
single representative experiment.
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Figure 22: PKC contribution to the synergistic release of IL-6 by IL-ip and 
TNF-a. Rat C6 cells were plated (125 x 10^ cells/well in a PDL-coated 96- 
well plate) and were pretreated with 0.7 nM STS for 1 hour and co-treated 
with 0.7 nM STS, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post 
stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. A (+) indicates 
that C6 glioma cells were treated with IL-ip, TNF-a, and the inhibitor; a (-) 
indicates that cells were treated with the inhibitor alone. The data are 
presented as mean ± s.e.m. of quadruplicate observations obtained from a 
single representative experiment.
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Synergistic Release of IL-6 by IL-ip and TNF-a: Role NF-k B 
Previous reports indicate that the NF-k B transcription factor is a key mediator 
in the induction of the IL-6 gene by both IL-ip and TNF-a (Berghe et al., 2000). 
To illustrate the importance of this transcription factor in the synergistic release of 
IL-6 by Tl, C6 cells were treated with two different inhibitors of NF-k B 
transcriptional activation: NAI and Bay 11-7082. Cells were pretreated for 1 hour 
with 25 pM Bay 11-7082 or 11 nM NAI (concentrations that were successful for 
the inhibition of transcriptional activation of NF-k B in 0 6  glioma and Jurkat cells, 
respectively, Davis et al., 2005; Tobe et al., 2003) and co-treated with either Bay 
11-7082 or NAI, 50 ng/mL IL-ip and 100 ng/mL TNF-a. As shown in Figure 23, 
only Bay 11-7082 was able to suppress the synergistic release of IL-6 by Tl. For 
example, a 95% suppression of IL-6 release was observed using Bay 11-7082 
(82.63 + 9.78 pg/mL versus 1541.22 ± 242.48 pg/mL for Tl). Conversely, no 
suppression was observed when NAI was used (1144.40 ± 200.97 pg/mL versus 
1541.22 ± 242.48 pg/mL for Tl). Taken together, these data suggest that [a] 
although both of these compounds are thought to inhibit NF-k B transcriptional 
activity, their mechanisms of action differ among cell types and [b] NF-k B 
transcriptional activity is essential for the synergistic release of IL-6 by Tl.
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Figure 23: NF-kB contribution to the synergistic release of IL-6 by IL-1p and 
TNF-a. Rat C6 cells were plated (125 x 10^ cells/well in a PDL-coated 96- 
well plate) and were pretreated with 25 pM Bay 11-7082 (panel A) or 11 nM 
NAI (panel B) for 1 hour and co-treated with either 25 pM Bay 11-7082 or 11 
nM NAI, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post 
stimulation, conditioned medium was removed and assayed for IL-6 using 
Pierce ELISA according to the manufacturer’s specifications. (C) Structural 
projections of Bay 11-7082 and NAI. A (+) indicates that C6 glioma cells were 
treated with IL-ip, TNF-a, and the inhibitor; a (-) indicates that cells were 
treated with the inhibitor alone. The data are presented as mean ± s.e.m. of 
quadruplicate observations obtained from a single experiment.
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Time- and Dose-Dependent Accrual of Phosphorylated p38: Anisomycin 
The protein translation inhibitor anisomycin was initially isolated from strains 
of the bacteria Streptomyces (Sobin, and Tanner, 1954). The alkaloid is 
reportedly a selective and potent stimulator of JNK and p38 phosphorylation in 
vitro (Kyrikis et al., 1994; Hazzalin et al., 1998). The ability of anisomycin to 
stimulate the phosphorylation of p38 in C6 glioma cells was assessed via SDS- 
PAGE followed by Western analysis. As presented in Figure 24A, anisomycin 
(15 pg/mL) produced a time-dependent accrual of cytoplasmic phosphorylated 
p38 MAPK beginning at 5 minutes (an effect that was maintained through 90 
minutes). Dose-dependent accumulation of phosphorylated p38 MAPK was 
maximal between 5 - 1 5  pg/mL; additionally, higher concentrations of anisomycin 
(e.g., 25 or 30 pg/mL) were less efficacious in stimulating p38 phosphorylation 
(Figure 24B). In all experiments, anisomycin did not alter total p38 protein levels 
(Figure 24). These data validate our ability to detect phosphorylated p38 via 
Western analysis.
Time- and Dose-Dependent Accrual of Phosphorylated p38: IL-ip  
Previously, SB203580 (structure shown in Figure 19) was shown to inhibit the 
IL-ip-stimulated release of IL-6 in the rat C6 glioma cell line. Those data 
strongly support the role of the p38 MAPK signaling module in IL-ip-stimulated 
release of IL-6 (Spangelo et al., 2004). The following studies were conducted in 
order to elucidate the mechanisms used in the IL-ip-stimulated release of IL-6. 
The efficacy of IL-ip to stimulate phosphorylation of p38 was assessed via SDS-
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Figure 24: Time- and dose-dependent accrual of phosphorylated p38 by 
anisomycin. Rat C6 cells ( 3 x 10 ® cells/dish in a PDL-coated 35 x 10 mm- 
dish) were treated with vehicle control (serum free RPMI-1640) for increasing 
periods of time (A) with 15 pg/mL anisomycin or increasing concentrations of 
anisomycin for 60 min (B). Post stimulation, cellular protein was extracted, 
and 25 |ig of total protein were subsequently separated via SDS-PAGE 
followed by Western analysis for phosphorylated or total p38 protein (1:1000 
for both). (C) Structural projection of anisomycin. The data are presented as 
the observations obtained from a single representative experiment.
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PAGE followed by Western analysis. As shown In Figure 25A, IL-ip (50 ng/mL) 
produced a biphasic time-dependent accumulation of phosphorylated p38 
detectable at 5 minutes and maximal at 15 minutes. Interleukin-1 (3 dose- 
dependently stimulated the phosphorylation of p38 from 5 - 1 0 0  ng/mL (Figure 
25B). In all experiments, IL-ip was unable to alter the levels of total p38 protein 
levels. These data support the results reported by Spangelo et al., indicating that 
p38 MAPK is an essential component of IL-1 signaling (2004).
Phosphorylation of MAPKs by IL-ip  
Pharmacological data obtained previously indicate that JNK and ERK are not 
essential for the IL-ip-stimulated release of IL-6. To further assess the ability of 
IL-ip to stimulate other MAPKs, C6 cells were treated with 50 ng/mL IL-ip for 15 
minutes, and probed for MAPK (p38, JNK or ERK) phosphorylation. Cellular 
protein was extracted and separated via 12% SDS-PAGE followed by Western 
analysis. As shown in Figure 26, 50 ng/mL IL-ip induced the accrual of the 
phosphorylated forms of p38, and JNK 1/2, but not ERK 1/2. In all treatments, 50 
ng/mL IL-ip were unable to alter the total levels of p38, JNK or ERK. Taken 
together, these data suggest a role for p38 and JNK in IL-ip-mediated signal 
transduction.
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Figure 25: Time- and dose-dependent accrual of phosphorylated p38 by IL- 
ip . Rat C6 cells (3 x 10® cells/dish in a PDL-coated 35 x 10 mm-dish) were 
treated with vehicle control (serum free RPMI-1640) for increasing periods of 
time (A) with 50 ng/mL IL-ip or increasing concentrations IL-ip for 15 min 
(B). Post stimulation, cellular protein was extracted, and 25 pg of total protein 
were subsequently separated via SDS-PAGE followed by Western analysis 
for phosphorylated or total p38 protein (1:1000 for both). The data are 
presented as the observations obtained from a single representative 
experiment.
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Figure 26: Accrual of phosphorylated MAPKs by IL-ip: Rat C6 cells ( 3x10®  
cells/dish in a PDL-coated 35 x 10 mm-dish) were treated with vehicle control 
(serum free RPMI-1640) for increasing periods of time with 50 ng/mL IL-ip or 
increasing concentrations IL-ip for 15 min. Post stimulation, cellular protein 
was extracted, and 25 jig of total protein were subsequently separated via 
SDS-PAGE followed by Western analysis for phosphorylated or total p38, 
JNK, or ERK proteins (1:1000 for all). The data are presented as the 
observations obtained from a single representative experiment.
69
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
Time and Dose-Dependent Acrual of Phosphorylated p38: TNF-a 
In light of the striking synergistic release of IL-6 seen by IL-ip and TNF-a, a 
possible mechanistic rationale was sought. The efficacy of TNF-a to stimulate 
phosphorylation of p38 was assessed via SDS-PAGE followed by Western 
analysis. As shown in Figure 27A, TNF-a (50 ng/mL) caused a biphasic-time- 
dependent phosphorylation of p38 with maximal immunoreactivity seen at 15 
minutes. Tumor necrosis factor-a also stimulated an increase in cytoplasmic 
phosphorylated p38 beginning at 5 ng/mL with no distinct change in the 
phosphorylation pattern up to 200 ng/mL (Figure 27B). In all experiments, TNF-a  
did not alter the levels of total p38 protein. Taken together, these data suggest 
that TNF-a is able to stimulate the phosphorylation of p38.
Effect of IL-ip and TNF-a co-lncubation on MAPK phosphorylation 
To ascertain the signaling mechanism involved in the synergistic release of 
IL-6, rat C6 cells were treated with 50 ng/mL IL-ip, 100 ng/mL TNF-a, or 50 
ng/mL IL-ip and 100 ng/mL TNF-a for 15 minutes, and examined for 
phosphorylation of p38, JNK and ERK. Post stimulation, cellular protein was 
extracted, separated by SDS-PAGE followed by Western analysis for 
phosphorylated or total MAPK. As shown in Figure 28, no additional increases in 
phosphorylated p38 were seen in C6 cells treated with 50 ng/mL IL-ip and 100 
ng/mL TNF-a. Additionally, similar results were noted for the phosphorylation of 
JNK. Similar to the study presented in Figure 26, ERK is not sensitive to 
stimulations by IL-ip, TNF-a or to the combined treatment of IL-ip and TNF-a.
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Figure 27: Time- and dose-dependent accrual of phosphorylated p38 by TNF- 
a. Rat C6 cells (3 x 10® cells/dish in a 35 x 10 mm-dish) were treated with 
vehicle control (serum free RPMI-1640) for increasing periods of time (A) with 
50 ng/mL TNF-a or increasing concentrations of TNF-a for 15 min (B). Post 
stimulation, cellular protein was extracted, and 25 ng of total protein were 
subsequently separated via SDS-PAGE followed by Western analysis for 
phosphorylated or total p38 protein (1:1000 for both). The data are presented 
as the observations obtained from a single representative experiment.
71
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
In all treatments, stimulation by IL-1p and TNF-a did not cause a change in total 
levels of MAPK protein.
Degradation of kB-a by IL-ip  
In an attempt to clarify the mechanism of the synergistic release of IL-6 by IL- 
ip  and TNF-a, the role of the NF-k B activation was investigated. Since the 
activity of NF-k B can be assessed though the degradation of its intrinsic inhibitor 
Ik B, C6 cells were treated with. 50 ng/mL IL-ip for 5, 15, 30, 60, or 90 minutes. 
Post stimulation, cytosolic protein was extracted and assayed for the degradation 
of kB-a via SDS-PAGE followed by Western analysis. As shown in Figure 29, 
50 ng/mL IL-ip caused a rapid and transient decrease in kB-a immunoreactivity 
at 15 and 30 minutes which coincided with the maximal accrual of 
phosphorylated p38 (Figure 29).
Degradation of kB-a by TNF-a 
The degradation of the intrinsic inhibitor kB in C6 cells treated with 50 ng/mL 
TNF-a for 5 - 9 0  minutes was also determined. Cytosolic protein was extracted 
and assayed for the presence of kB-a via SDS-PAGE followed by Western 
analysis. As shown in Figure 30, 50 ng/mL TNF-a caused a rapid and transient 
decrease in kB-a at 15 and 30 minutes, which strongly coincided with the 
maximal accrual of phosphorylated p38 MAPK.
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Figure 28: Accrual of phosphorylated MAPKs by IL-ip and TNF-a. Rat C6 
cells ( 3x10® cells/dish in a PDL-coated 35 x 10 mm-dish) were treated with 
vehicle control (serum free RPMI-1640), 50 ng/mL IL-ip, 100 ng/mL TNF-a or 
both IL-ip and TNF-a for 15 min. Post stimulation, cellular protein was 
extracted and 25 |xg (10 pg for ERK) of total protein was subsequently 
separated via SDS-PAGE followed by Western Analysis for phosphorylated or 
total p38, JNK, or ERK proteins (1:1000 for all). The data are presented as 
the observations obtained from a single representative experiment.
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Figure 29: Time-dependent degradation of kB -a  by IL-1 p. Rat C6 cells (3 x 
10® cells/dish in a PDL-coated 35 x 10 mm-dish) were treated with vehicle 
control (serum free RPMI-1640) or increasing periods of time with 50 ng/mL 
IL-ip. Post stimulation, cellular protein was extracted, and 25 ^g of total 
protein was subsequently separated via SDS-PAGE followed by Western 
analysis for kB -a , kB-p, phosphorylated or total p38 protein (1:1000 for all). 
The data are presented as the observations obtained from a single 
representative experiment.
74
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
k B -a
IkB-P
phosphorylated p38
0 5 15 30 60 90
total p38
(min)
Figure 30: Time-dependent degradation of kB-a by TNF-a. Rat C6 cells (3 x 
1 (r cells/dish in a 35 x 10 mm-dish) were treated for increasing periods of 
time with 50 ng/mL TNF-a. Post stimulation, cellular protein was extracted, 
and 25 ^g of total protein was subsequently separated via SDS-PAGE 
followed by Western Analysis for kB-a, kB-p, phosphorylated or total p38 
protein (1:1000 for all). The data are presented as the observations obtained 
from a single representative experiment.
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Degradation of kB-a: Role of p38 and GABA 
Although activation of NF-k B and MAPKs are postulated to be parallel events, 
Jang et al., have reported that the p38 inhibitor SB203580 can subdue Ap- 
stimulated binding of NF-k B to its cognate sequence as assessed by the 
electrophoretic mobility shift assay (EMSA) in the P C I2 rat pheochromocytoma 
cell line (2005). These data indicate that p38 is indispensable for NF-k B 
transcriptional activity in neurons. To elucidate the role of p38 in the degradation 
of kB -a, C6 glioma cells were treated with 10 i^M SB203580 for 1 hour and 
stimulated with 50 ng/mL IL-ip and 100 ng/mL TNF-a for 15 min. Post 
stimulation, cellular protein was extracted and separated using SDS-PAGE 
followed by Western analysis. As shown in Figure 31, inhibition of p38 activity 
did not suppress degradation of kB -a. Furthermore, a 1 hour pre-treatment with 
1 mM GABA followed by a 15 minute co-treatment with 1 mM GABA, 50 ng/mL 
IL-ip and 100 ng/mL TNF-a was also unable to suppress the degradation of kB - 
a. Taken together, these data suggest that glial p38 does not mediate NF-k B 
activation. Additionally the GABA-mediated suppression of synergistic astrocytic 
IL-6 release may not involve NF-k B activation. No stimulation was able to alter 
total levels of p38 protein.
Degradation of kB -a: Effects of Lower TNF-a Concentrations 
In all studies presented, C6 cells were treated with 50 ng/mL IL-ip and 100 
ng/mL TNF-a. The data shown in Figure 27, indicate that 5 ng/mL TNF-a  
stimulates the phosphorylation of p38, with no further increases in
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Figure 31: The role of p38 in the degradation of kB -a . Rat C6 cells (3x10®  
cells/dish in a 35 x 10 mm-dish) were pre-treated with 10 pM SB203580 or 1 
mM GABA for 1 hour, and co-treated with either 10 pM SB203580 or 1 mM 
GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 15 min. Post stimulation, 
cellular protein was extracted, and 25 |ag of total protein were subsequently 
separated via SDS-PAGE followed by Western analysis for kB -a, kB-p, 
phosphorylated or total p38 protein (1:1000 for all). A (+) represents a 
treatment group where C6 glioma cells were treated with both IL-ip and TNF- 
a; a (-) indicates that C6 glioma cells were treated with the inhibitor alone. 
The data are presented as the observations obtained from a single 
experiment.
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phosphorylated p38 immunoreactivity at higher doses (i.e., 200 ng/mL TNF-a). 
We postulate that treatment of C6 glioma cells with 50 ng/mL IL-ip and lower 
concentrations of TNF-a may allow for a synergistic stimulation of 
p38phosphorylation and a concurrent degradation of kB-a. As shown in Figure 
32, kB-a degradation was accelerated by either 5 or 50 ng/mL TNF-a in the 
presence of 50 ng/mL IL-1p (i.e., compare Tl treatments to IL-ip or TNF-a 
alone). Taken together, these data indicate that the phoshorylation of p38 and 
the degradation of kB-a can be further stimulated by decreasing TNF-a  
concentrations in the presence of 50 ng/mL IL-1 p.
Degradation of kB-a: Roles of PKA and PKC 
The ability of 0.7 nM STS to inhibit the synergistic release of IL-6 by Tl 
(Figure 22) prompted the investigation of the ability of this treatment to inhibit the 
degradation of either kB-a or phosphorylation of p38. As shown in Figure 33, 
the pretreatment of C6 cells with 0.7 nM STS ( I C 5 0  for PKC inhibition) 
subsequent stimulation with 50 ng/mL IL-ip and 100 ng/mL TNF-a did not inhibit 
the degradation of kB-a or phosphorylation of p38. Additionally, treatment of C6 
cells with 7 nM STS ( I C 5 0  for PKA inhibition) resulted in no change in the 
degradation and phosphorylation patterns of kB-a and p38, respectively.
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Figure 32: Effects of lower TNF-a concentration on p38 phosphorylation and 
the degradation of kB-a. Rat C6 cells (3x10® cells/dish in a PDL-coated 35 
X 10 mm-dish) were pretreated with either 5 ng/mL or 50 ng/mL TNF-a in the 
absence or presence of 50 ng/mL IL-ip for 15 min. Post stimulation, cellular 
protein was extracted, and 25 )ig of total protein was subsequently separated 
via SDS-PAGE followed by Western analysis for kB -a, phosphorylated or 
total p38 protein (1:1000 for all). A (+) represents a treatment group where 
C6 glioma cells were treated with both IL-ip and TNF-a; a (-) indicates that 
C6 glioma cells were treated with the TNF-a alone. The data are presented 
as the observations obtained from a single experiment.
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Figure 33: The roles of PKA and PKC in the degradation of kB-a. Rat C6 
cells (3 X 10® cells/dish in a PDL-coated 35 x 10 mm-dish) were pre-treated 
with 7 nM or 0.7 nM mM STS for 1 hour, and co-treated with either 7 nM or 
0.7 nM STS, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 15 min. Post 
stimulation, cellular protein was extracted, and 25 |o,g of total protein was 
subsequently separated via SDS-PAGE followed by Western analysis for kB- 
a  phosphorylated or total p38 protein (1:1000 for all). A (+) represents a 
treatment group where C6 glioma cells were treated with both IL-ip and TNF- 
a; a (-) indicates that C6 glioma cells were treated with the inhibitor alone. 
The data are presented as the observations obtained from a single 
experiment.
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Inhibition of NF-kB and Degradation of kB -a  
The data presented thus far strongly suggest a role for NF-kB in the 
synergistic release of IL-6 by Tl. To further ascertain a mechanistic rationale for 
this release of IL-6, inhibitors of NF-kB activation were used to monitor the 
degradation of kB -a. As shown in Figure 34, a 1 hour pretreatment for with 11 
nM NAI (Tobe et al., 2003) followed by a 15 minute co-treatment with 11 nM NAI, 
50 ng/mL IL-ip and 100 ng/mL TNF-a was unable to suppress the degradation of 
kB -a  as indicated though SDS-PAGE followed by Western analysis. 
Conversely, a 1 hour pretreatment with 25 |iM Bay 11-7082 followed by a 15 min 
co-treatment with 25 p,M Bay 11-7082, 50 ng/mL IL-ip and 100 ng/mL TNF-a  
was able to suppress the degradation of kB -a  and the phosphorylation of p38. 
These data are consistent with the ELISA release data presented in Figure 23, 
and indicate the mechanism of action for these two inhibitors are completely 
different from each other.
Dose-Dependent Inhibition of kB-a Degradation by Bay 11-7082 
To determine the dose-dependent inhibition of kB-a degradation by Bay 11- 
7082, in the presence of IL-ip and TNF-a, C6 glioma cells were co-treated with 
either 10 or 25 jj,M Bay 11-7082, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 15 
minutes. As indicated though SDS-PAGE followed by Western analysis (Figure 
35), 25 jj,M but not 10 |iM Bay 11-7082 was able to preserve kB-a protein within 
the cells in the presence of Tl. Additionally, 25 pM but not 10 pM Bay 11-7082
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was able to produce a modest reduction of phosphorylated p38 immunoreactivity 
in the presence of Tl. As expected, no changes in total p38 or kB-p proteins 
were observed over all treatments. These data suggest that the abilities of Bay 
11-7082 to prevent the release of IL-6 and the degradation of kB -a  in the 
presence of Tl is dependent on the concentration of the small molecule inhibitor.
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Figure 34: Inhibitors of NF-kB and degradation of kB -a . Rat C6 cells (3x10® 
cells/dish in a PDL-coated 35 x 10 mm-dish) were pretreated with either 11 
nM NAI, 25 |.iM Bay 11-7082 or 10 pM SB202190 for 1 hour, and co-treated 
with either NAI, Bay 11-7082 or SB202190, 50 ng/mL IL-ip and 100 ng/mL 
TNF-a for 15 min. Post stimulation, cellular protein was extracted, and 25 pg 
of total protein were subsequently separated via SDS-PAGE followed by 
Western analysis for kB -a  phosphorylated or total p38 protein (1:1000 for 
all). A (+) represents a treatment group where C6 glioma cells were treated 
with both IL-ip and TNF-a; a (-) indicates that C6 glioma cells were treated 
with the inhibitor alone. The data are presented as the observations obtained 
from a single experiment.
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Figure 35: Dose-dependent degradation of kB -a  by Bay 11-7082. Rat C6 
cells (3x10® cells/dish in a PDL-coated 35 x 10 mm-dish) were treated with 
50 ng/mL IL-ip and 100 ng/mL TNF-a in the presence or absence of 10 pM 
or 25 |j,M Bay 11-7082 for 15 min. Post stimulation, cellular protein was 
extracted, and 25 |o.g of total protein were subsequently separated via SDS- 
PAGE followed by Western analysis for kB -a, kB-p, phosphorylated or total 
p38 protein (1:1000 for all). A (+) represents a treatment group where C6 
glioma cells were treated with the inhibitor, IL-ip and TNF-a; a (-) indicates 
that C6 glioma cells were treated with the inhibitor alone. The data are 
presented as the observations obtained from a single experiment.
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CHAPTER 4 
DISCUSSION
Glutamate-Mediated Excitotoxicity in the B35 Neuroblastoma Cell Line 
The aberrant release and subsequent metabolism of the primary excitatory 
neurotransmitter Glu has been implicated in AD, epilepsy and ischemia 
(Obrenovitch et al., 2000). Superfluous concentrations of perisynaptic Glu are 
reported to encourage excessive NMDA receptor activation, leading to an 
increased Ca^  ̂ influx into the cell and a dissemination of excitotoxic events 
(Figure 36). The use of memantine (Figure 2), a low to moderate non-competitive 
inhibitor of NMDA receptor activation by Glu, has shown clinical promise in 
treating AD patients with severe dementia. There are accumulating amounts of 
evidence indicating that pro-inflammatory cytokines (e.g., IL-ip, TNF-a and IL-6) 
have the propensity to further exacerbate the already compromised aspects of 
glutamatergic neurotransmission, NMDA receptor activation and metabolism in 
AD (Hu et al., 2000; Viviani et al., 2003; Floden et al., 2005). Much effort has 
been made to elucidate the mechanisms in which pro-inflammatory cytokines 
and/or signal transduction pathways affect aspects of glutamatergic 
neurotransmission, receptor activation and metabolism (Qiu and Gruol, 2003; Wu
85
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
metabolic
interconversion
NEURON
glutamate
glutamine
ASTROCYTE
co-agonistsexcitatory neurotransmitter
GLYCINE SITE 
NEUROMODULATORS
glycine
D-serine
ION CHANNEL 
ANTAGONISTS
memantine
MK-801
phencyclidine positive calcium fiux
DISSEMINATION OF 
EXCITOTOXIC 
PROCESæS
Figure 36: Consequences associated with prolonged NMDA receptor 
activation by Glu.
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et al., 2004; Takahashi et al., 2003; Chaparro-Huerta et al., 2005; Pelldou et al., 
2002).
The rat B35 neuroblastoma cell line was chosen as a model cell line in which 
to study the signal transduction mechanisms involved in glutamatergic 
neurotransmission and subsequent NMDA receptor activation. Numakawa et al. 
demonstrated that primary rat cortical neurons release Glu when stimulated with 
either BFGF and/or 50 mM (2000). In an attempt to ascertain the role IL-ip  
could have on the release of Glu, HPLC determination of amino acids (n.b., Glu) 
was implemented. As presented in Figure 10 and 11, the assay for the 
quantification of Glu was properly developed; however, much to our 
disappointment, B35 cells were unresponsive to either depolarizing 
concentrations of and/or IL-ip (Figure 11). The fact that GABA is a major 
cellular product may explain the unresponsiveness of B35 cells to the 
aforementioned stimulus (Schubert et al., 1974). While it could be true that 
GABA could be released under the experimental conditions, the size of the 
column (5 cm) and solvent program was optimized for Glu and not GABA.
The finding that STS is able to cause a dose-dependent decrease of cell 
viability (Figure 12) provided a foundation on which to further elucidate the role of 
pro-inflammatory cytokines in Glu-mediated excitotoxicity. In two separate 
studies (i.e., passage numbers 29 and 30), Glu was able to induce a dose- 
dependent decrease in cell viability (Figure 13). Again to our disappointment, 
new lines of B35 cells were completely unresponsive to the same concentrations 
of Glu at a low and high passage number (9 and 20), and to an overnight
87
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
incubation in reduced serum conditions (Figure 14). Two previous reports 
indicate that the all-frans-retinoic acid (RA)-induced differentiation of the human 
SK-N-SH neuroblastoma and NT2 teratocarcinoma cell lines produce functional 
NMDA receptors capable of mediating excessive Glu stimulation though NMDA 
receptors (Pizzi et al., 2002; Younkin et al., 1993). Although not reported in the 
primary literature, it is plausible that RA-induced differentiation of the rat B35 
neuroblastoma cell line may cause the expression of functional NMDA receptors. 
In summary, the inability of the rat B35 neuroblastoma cell line to respond to pro- 
inflammatory or excitotoxic stimulus may be due to an intrinsic characteristic of 
the cell line (i.e., GABAergic neuron unable to express functional NMDA 
receptors).
Synergistic Release of IL-6 by IL-ip and TNF-a  
Blockade of the increased production of pro-inflammatory cytokines in AD 
may lead to novel modalities to treat this catastrophic disorder (Ranaivo et al., 
2006; Allan and Pinteaux, 2003; Braddock and Quinn, 2004). Elucidation of the 
signal transduction pathways used by IL-ip may identify potential targets to 
which pharmacological inhibitors may be used to break the recursive cascade 
present in the amyloid cascade hypothesis. A core focus of the Spangelo 
laboratory has been to ascertain the mechanism of the IL-ip-stimulated release 
of IL-6 in the rat C6 glioma cell line. Previous reports from the laboratory indicate 
that the IL-1p-stimulated release of IL-6 is sensitive to cyclic adenosine 3 - 5 ’ 
monophosphate (cAMP), catecholamines, TNF-a, SRIF, and the primary 
inhibitory neurotransmitter GABA (Zumwalt et al., 1999; Spangelo et al., 2004).
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These data suggest that the release of IL-6 is controlled by a multitude of factors. 
The ability of TNF-a to synergistically stimulate the IL-ip-stimulated release of IL- 
6 presents an interesting discovery because increased levels of TNF-a have 
been seen in AD (Dickson et al., 1993). Additionally, the dysfunction of 
numerous neurotransmitter systems (i.e., GABAergic) may provide insight into 
the reasons why elevated levels of pro-inflammatory cytokines exist in AD 
neuropathology (Bell et al., 2005). The studies presented within this work 
attempt to provide a mechanistic rationale for both the synergistic release of IL-6 
by Tl (Figure 18) as well as the GABA-mediated inhibition of this effect (Figure 
20).
Spangelo et al. have suggested that the p38 (1996) and PKC signaling 
modules (2004) are both essential for the release of IL-6 by IL-ip or its putative 
second messenger lysophosphatidylcholine (LPC) in the C6 glioma cell line and 
in primary rat anterior pituitary cells, respectively. The relative importance of 
these kinases (i.e., p38 and PKC) is in accord with existing reports suggesting 
that increased activities of both of these kinases are present during AD. 
Inhibition of p38 with SB203580, or its hydroxy-phenyl analog, SB202190, 
blocked the synergistic release of IL-6 from the 0 6  glioma cell line (Figure 19A, 
and B): moreover, inhibition with the broad range PKC inhibitor, STS, also 
effectively suppressed immunoreactive IL-6 release caused by Tl (Figure 22).
The promoter region of the rat IL-6 gene contains AP-1, cAMP response 
element (CRE) and NF-kB binding sites (Li et al, 2004) (Table 3). The presences 
of these binding sites provide pertinent information with which to elucidate the
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mechanistic basis for the synergistic release of IL-6 by IL-ip and TNF-a. Nuclear 
factor-KB has been implicated in the production of IL-6 by Tl (Sparacio et al., 
1992): furthermore, Moynagh et al. reported that both IL-1a and IL-ip are able to 
activate NF-kB in C6 glioma cells (1993). Pradeep and Kuttan reported that 
piperine treatment of B16F-10 melanoma cells resulted in a decreased 
expression of pro-inflammatory cytokines such as IL-ip, IL-6, TNF-a and others 
through a decreased nuclear translocation of transcription factors such as cAMP 
response element binding protein (CREB) and NF-kB (2004). While many other 
reports exist, the abilities of IL-ip and TNF-a to increase NF-kB transcriptional 
activation provide a foundation in which to study the synergistic release of IL-6 in 
C6 glioma cells.
Activation of the “canonical” p50-p65 NF-kB heterodimeric transcription factor 
has been reported to be dependent (Jang et al., 2005) and independent (Fiebich 
et al., 2000; Wu et al., 2004) of p38 activation. Additionally, Jang and Surh have 
reported that AP-1-mediated transcription is dependent on p38 activation 
(2005B). Although these reports are based on different cell types (PC12, SK-N- 
SH and primary rat astrocytes), it is plausible that activation of p38 by IL-ip  
and/or TNF-a leads to a concomitant increase in NF-kB activation in the C6 
glioma cell line. The abilities of IL-ip and/or TNF-a to stimulate the 
phosphorylation of p38 was investigated; however, while each of these cytokines 
alone are able to stimulate phosphorylation of p38, the combined presence of 
these cytokines were unable to cause reproducible synergistic increases in p38
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Binding Site Consensus Sequence
AP-1 5-AGTCA-3'
CRE 5-CGTCA-3'
NF-k B 5-GGGATTTTCCC-3'
Table 3; Transcription factor binding sites present in the rat IL-6 gene.
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phosphorylation (Figure 28). Although NF-kB activation can be determined by 
the separation of nuclear protein via SDS-PAGE followed by Western analysis, 
the nuclear translocation of NF-kB can also be monitored by the degradation of 
its inhibitory factor, IkB. Three isoforms of IkB currently exists (a, p and s) and 
prior publications indicate that kB-a is sufficient for monitoring the liberation of 
the free NF-kB p50-p65 heterodimer. As shown in Figures 31 and 34, blockade 
of p38 activity using SB203580 or its hydroxyl-phenyl analog, SB202190 were 
unable to suppress the degradation of kB-a when treated with IL-ip and TNF-a. 
These data indicate that [a] SB203580 and SB202190 do not inhibit 
phosphorylation of p38 itself, but rather prevent this kinase from activating a 
downstream target and [b] inhibition of p38 activity does not result in the reversal 
of kB-a degradation by IL-ip and/or TNF-a. In contrast to Jang et al. who 
reported SB203580-mediated suppression of the Ap-mediated binding of AP-1 
and NF-kB to a labeled oligonucleotide probe for AP-1 and NF-kB in the pro­
neuronal-like PC 12 pheochromocytoma cell line, the data collected in the C6 
glioma cell line suggest that p38 is dispensable for N F-kB  activity as monitored 
by kB-a degradation (2005; 2005B). The discrepancy seen between Jang et al. 
(2005B) and the data presented in this study are supported by the observations 
of Srinivasan et al. who demonstrate that IL-ip is able to increase binding of NF- 
kB  to a labeled oligonucleotide probe for NF-kB in primary rat astrocytes, but not 
in hippocampal neurons (2004).
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The synergistic release of IL-6 by Tl was also sensitive to non-specific 
inhibition of PKC, but not PKA by using 0.7 and 7 nM STS, respectively (Figure
22). Consistent with the lack of inhibition of p38 phosphorylation, 0.7 nM STS 
was unable to prevent the degradation of k B -a  in the C6 glioma cell line (Figure 
33). Inhibition of PKC using bisindolylmaleimide was shown to prevent the IL-ip- 
stimulated phosphorylation of ERK in primary murine astrocytes suggesting that 
PKC is essential for ERK activity (Molina-Holgado et al., 2000). As presented in 
Figure 33, inhibition of PKC with 0.7 nM STS was unable to mitigate the 
phosphorylation of p38 by Tl. Taken together, these data suggest that PKC and 
p38 do not cooperate with respect to IL-6 release by TL
Human Ap pentapeptides (either 31-35 or 34-39) are reportedly neurotoxic to 
GABAergic neurons isolated from primary rat forebrain cultures (Pakaski et al., 
1998). Furthermore, Samland et al. have reported that transgenic mice 
expressing IL-6 from the glial fibrillary acidic protein (GFAP) promoter show a 
decrease in immunostaining for GABAergic neurons beginning at 2-months of 
age, suggesting that IL-6 is detrimental to GABAergic neuron viability (2003). 
These results suggest that levels of the primary inhibitory neurotransmitter GABA 
are decreased in AD. The exogenous administration of inhibitory 
neurotransmitters could be of a therapeutic benefit in AD. Craft et al. have 
reported that administration of the SRIF (inhibitory neuropeptide) analog 
octreotide, enhances the memory of AD patients in story recall (1999). Spangelo 
et al. have reported that both SRIF and GABA are able to attenuate the IL-ip- 
stimulated release of IL-6 from C6 glioma cells (2004). As shown in Figure 20,
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GABA is also able to inhibit the synergistic release of IL-6 by Tl. In contrast to 
our preliminary studies suggesting that GABA suppression of IL-ip-stimulated IL- 
6 release is mediated by a reduction in p38 phosphorylation (data not shown), 
the data presented in Figure 31 show no GABAergic effect on phosphorylated 
p38. GABA was also unable to suppress the IL-ip-stimulated phosphorylation of 
p38 in the C6 glioma cell line in the presence of Tl. These results contradict 
those of Simi et al., who observed that chlomethiazole (a GABAa receptor 
agonist) is able to produce a neuroprotective effect in lipopolysaccahride (LPS)- 
stimulated primary cortical glial cultures through a decrease in p38 
phosphorylation (2000).
The individual signal transduction pathways used by IL-ip and TNF-a 
converge upon the activation of NF-kB (Akama and Van Eldik, 2000). The data 
presented in Figure 32 indicate that lowering TNF-a concentrations may allow for 
a synergistic stimulation of p38 phosphorylation. More importantly. Figure 32 
shows that the degradation of kB-a can be greatly accelerated by the co­
treatment of IL-ip and TNF-a. Bourke et al., have reported that signaling by IL- 
ip to NFkB is mediated though the long-term degradation of kB-p instead of the 
transient degradation of kB-a (2000). Interestingly, the data obtained from this 
study indicate that IL-ip or TNF-a is unable to stimulate the degradation of kB-p. 
Taken together these findings strengthen the suggestion that the synergistic 
release of IL-6 by Tl could be dependent upon the accelerated degradation of 
kB-a. The ability of Bay 11-7082 to prevent both the degradation of kB-a 
(Figure 34) and the synergistic release of IL-6 (Figure 23) may provide clues into
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the mechanistic action of GABA. GABA’s inability to lessen p38 phosphorylation 
while inhibiting the release of IL-6, suggests that GABA’s ability to inhibit the 
synergistic release of IL-6 could be through a lessened rate of degradation of 
kB-a. While one may suggest that GABA could prevent the degradation of kB- 
a altogether, the data presented rule against this mechanism. Juxtaposition of 
the ELISA release data obtained by GABA (Figure 20) and Bay 11-7082 (Figure
23) with the data illustrating the effects of these two agents on kB-a degradation 
(Figures 31 and 34, respectively) clearly indicate that even though GABA is able 
to provide a ~60% suppression of IL-6 release, GABA is unable to prevent kB-a 
degradation. In sharp contrast to GABA, 25 pM Bay 11-7082 is able to produce 
an unsurpassed -95%  suppression of IL-6 release (Figure 23) and a complete 
prevention of kB-a degradation (Figures 34 and 35). W e suggest that GABA’s 
ability to suppress IL-6 release maybe mediated by a decreased rate of kB-a 
degradation. Phosphorylation of kB initiates the process for degradation. We 
will investigate the effects of GABA on the phosphorylation of this protein in the 
presence of a proteasomal inhibitor such as pyrrolidine dithiocarbamate (PDTC) 
or MG132. W e will also conduct a kinetic study (using SDS-PAGE followed by 
Western analysis) of GABA’s ability to lessen the rate of kB-a degradation.
The work presented made use of the rat C6 glioma cell line, while there are 
many advantages to using an immortalized cell line (i.e., rapid doubling time and 
no animal surgery procedures), the generation and use of rat primary type I 
astrocytes would allow for a more physiologically relevant platform (i.e., no 
aberrant growth and/or signaling mechanisms) in which this mechanistic study
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can take place. W e are currently working to establish primary cultures of rat type 
I astrocytes such that select experiments presented within this work can be 
replicated using a non-immortalized cell type.
Occupancy of the IL -I-R 1 and TNF receptor (TNFR) by IL-ip and TNF-a, 
respectively, stimulates the activity of the MAPKKK branch point kinase (Figure 
37). Activation of MAPKKK leads to a signal bifurcation into the p38 and NF-kB 
signaling modules culminating in the synergistic release of IL-6 from C6 glioma 
cells. The use of SB203580 or SB202190 is able abrogate the synergistic 
release of IL-6 without an inhibition of p38 phosphorylation (Figures 31 and 34). 
Similarly, Bay 11-7082 is able inhibit the release of IL-6 (Figure 23) while 
preventing kB-a degradation in the presence of Tl (Figures 34 and 35). GABA is 
postulated to diminish the rate of kB-a degradation leading to the -60%  
suppression of IL-6 release synergistically driven by Tl. The finding that both 
SB203580 and SB202190 is unable to prevent kB-a degradation while inhibiting 
the release of IL-6 suggest that NF-kB activation is essential but not sufficient for 
the synergistic release of IL-6 by Tl.
Although both of the stated hypotheses were disproved, the data presented 
within this work suggest that the mechanistic basis for the synergistic release of 
IL-6 by Tl lies within the ability of these cytokines to synergistically enhance the 
rate of degradation of k B -a  leading to increased NF-k B activity. Furthermore, 
GABA’s ability to antagonize the synergistic release of IL-6 by Tl is postulated to 
be through a suppressed rate of kB -a  degradation. Verification of these
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mechanisms could lead to novel treatments able combat this catastrophic 
neurodegenerative disorder that is AD.
97
R eproduced  with perm ission o f the copyright ow ner. Further reproduction prohibited w ithout perm ission.
IL-1-R TNFR
MAPKKK
T
SB203580
SB202190
MKK3/6
I
p38
IKK ► — Bay 11-7082
I
ATF-2
{kB-œ-NF-kB ^
I
NF-kB
GABA
synergistic 
release of IL-6
Figure 37: Postulated signaling scheme for the synergistic release of IL-6 by 
IL-ip and TNF-a in C6 glioma cells.
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